Theralink (THER) 10-K 27 Sep 21 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Sep. 30, 2020	Sep. 22, 2021	Mar. 31, 2021
Cover [Abstract]
Entity Registrant Name	THERALINK TECHNOLOGIES, INC.
Entity Central Index Key	0001362703
Document Type	10-K
Document Period End Date	Sep. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	No
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 2,100,000
Entity Common Stock, Shares Outstanding		5,555,474,594
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2020
Entity Incorporation, State or Country Code	NV
Entity File Number	000-52218

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2020	Sep. 30, 2019
CURRENT ASSETS:
Cash	$ 1,779,283	$ 560,407
Other receivable	15,000	4,000
Prepaid expenses and other current assets	191,253	9,054
Marketable securities	11,100	18,000
Laboratory supplies	71,335
Total Current Assets	2,067,971	591,461
OTHER ASSETS:
Property and equipment, net	744,822	298,910
Finance right-of-use assets, net	157,691	204,059
Operating right-of-use asset, net	206,203
Security deposits	19,464	7,790
Total Assets	3,196,151	1,102,220
CURRENT LIABILITIES:
Accounts payable	617,218	668,246
Accrued liabilities	56,728	48,241
Accrued compensation	32,791	297,056
Accrued director compensation	72,500	70,000
Convertible debt, net		217,591
Notes payable - current	1,000	40,000
Financing lease liability - current	42,234	35,096
Operating lease liability - current	35,943
Insurance payable	63,675
Due to related parties		180,000
Contingent liabilities	64,040
Assumed liabilities of discontinued operations	204,608
Total Current Liabilities	1,190,737	1,556,230
LONG-TERM LIABILITIES:
Financing lease liability	136,116	178,350
Operating lease liability	176,893
Total Liabilities	1,503,746	1,734,580
Series E preferred stock; $0.0001 par value; 2,000 authorized; 1,000 and nil issued and outstanding at September 30, 2020 and 2019, respectively	2,000,000
STOCKHOLDERS' DEFICIT:
Preferred stock value
Common stock: $0.0001 par value, 12,000,000,000 shares authorized; 5,124,164,690 and nil issued and outstanding at September 30, 2020 and 2019, respectively	512,416
Additional paid-in capital	42,367,577	37,378,841
Accumulated deficit	(43,187,588)	(38,011,201)
Total Stockholders' Deficit	(307,595)	(632,360)
Total Liabilities and Stockholders' Deficit	3,196,151	1,102,220
Series A Preferred Stock [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock value
Total Stockholders' Deficit
Series C-1 Preferred Stock [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock value
Total Stockholders' Deficit
Series C-2 Preferred Stock [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock value
Total Stockholders' Deficit
Series D-1 Preferred Stock [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock value
Total Stockholders' Deficit
Series D-2 Preferred Stock [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock value
Total Stockholders' Deficit

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2020	Sep. 30, 2019
Temporary equity, par value	$ 0.0001	$ 0.0001
Temporary equity, authorized	2,000	2,000
Temporary equity, issued	1,000
Temporary equity, outstanding	1,000
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	26,667	26,667
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	12,000,000,000	12,000,000,000
Common stock, shares issued	5,124,164,690
Common stock, shares outstanding	5,124,164,690
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,333	1,333
Preferred stock, shares issued	667
Preferred stock, shares outstanding	667
Series C-1 Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	3,000	3,000
Preferred stock, shares issued	2,966
Preferred stock, shares outstanding	2,966
Series C-2 Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	6,000	6,000
Preferred stock, shares issued	4,917
Preferred stock, shares outstanding	4,917
Series D-1 Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000	1,000
Preferred stock, shares issued		992
Preferred stock, shares outstanding		992
Series D-2 Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	4,360	4,360
Preferred stock, shares issued
Preferred stock, shares outstanding

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
REVENUES, NET	$ 181,229
COST OF REVENUE	52,587
GROSS PROFIT	128,642
OPERATING EXPENSES:
Professional fees	925,626	455,893
Consulting fee - related party	70,125	235,392
Compensation expense	1,285,858	375,712
Licensing fees	51,670	51,546
General and administrative expenses	1,152,153	366,592
Total Operating Expenses	3,485,432	1,485,135
LOSS FROM OPERATIONS	(3,356,790)	(1,485,135)
OTHER INCOME (EXPENSE):
Interest expense	(31,218)	(66,799)
Gain on debt extinguishment	165,439
Unrealized loss on marketable securities	(6,900)	(15,800)
Loss on legal judgement		(30,100)
Gain on exchange rate, net	49,202
Other income	10,000
Total Other Income (Expense), net	186,523	(112,699)
NET LOSS	(3,170,267)	(1,597,834)
Preferred stock dividend and deemed dividend	(2,006,120)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	$ (5,176,387)	$ (1,597,834)
NET LOSS PER COMMON SHARE:
Basic and Diluted	$ (0.06)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic and Diluted	84,657,988

Consolidated Statement of Chang

Consolidated Statement of Changes in Stockholders' Equity (Deficit) - USD ($)	Series A Preferred Stock [Member]	Series C-1 Preferred Stock [Member]	Series C-2 Preferred Stock [Member]	Series D-1 Preferred Stock [Member]	Series D-2 Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Sep. 30, 2018							$ 35,600,822	$ (36,413,367)	$ (812,545)
Balance, shares at Sep. 30, 2018				961
Preferred stock issued for cash							1,599,469		1,599,469
Preferred stock issued for cash, shares				5
Common stock issued for services							100		100
Common stock issued for services, shares				26
Preferred stock issued upon debt conversions							125,000		125,000
Preferred stock issued upon conversion of related party advances							53,450		53,450
Net loss								(1,597,834)	(1,597,834)
Balance at Sep. 30, 2019							37,378,841	(38,011,201)	(632,360)
Balance, shares at Sep. 30, 2019				992
Preferred stock issued for cash							2,590,000		2,590,000
Preferred stock issued for cash, shares				7
Preferred stock issued upon debt conversions							217,215		217,215
Preferred stock issued upon conversion of accounts payable and accrued liabilities							459,153		459,153
Preferred stock issued upon conversion of accounts payable and accrued liabilities, shares				1
Recapitalization resulting from the Asset Sale Transaction (see Note 3)						$ 140	246,516		246,656
Recapitalization resulting from the Asset Sale Transaction (see Note 3), shares	667	2,966	4,917		4,121	1,398,070
Common stock issued for upon conversion of Series D-1 preferred stock						$ 508,155	(508,155)
Common stock issued for upon conversion of Series D-1 preferred stock, shares				(1,000)		5,081,550,620
Common stock issued for upon conversion of Series D-2 preferred stock						$ 4,121	(4,121)
Common stock issued for upon conversion of Series D-2 preferred stock, shares					(4,121)	41,216,000
Offering cost paid related to sale of Series E preferred stock							(11,872)		(11,872)
Series E preferred stock dividend and deemed dividend							2,000,000	(2,006,120)	(6,120)
Net loss								(3,170,267)	(3,170,267)
Balance at Sep. 30, 2020						$ 512,416	$ 42,367,577	$ (43,187,588)	$ (307,595)
Balance, shares at Sep. 30, 2020	667	2,966	4,917			5,124,164,690

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
CASH FLOWS USED IN OPERATING ACTIVITIES
Net loss	$ (3,170,267)	$ (1,597,834)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	97,761	47,540
Lease cost	6,633
Stock issued for services		100
Amortization of debt discount		25,000
Gain on debt extinguishment	(165,439)
Unrealized gain on exchange rate	(49,202)
Unrealized loss on marketable securities	6,900	15,800
Change in operating assets and liabilities:
Prepaid expenses and other current assets	(194,994)	(16,512)
Accounts payable	46,341	177,449
Accrued liabilities and other liabilities	(48,488)	126,657
Due to related parties		101,919
NET CASH USED IN OPERATING ACTIVITIES	(3,470,755)	(1,119,881)
CASH FLOWS FROM INVESTING ACTIVITIES
Cash acquired from the Asset Sale Transaction (see Note 3)	675,928
Purchase of property and equipment	(531,538)	(38,232)
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	144,390	(38,232)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of preferred stock	4,590,000	1,599,469
Proceeds from convertible debt, net of debt discount		100,000
Proceeds of related party advances, net		115,050
Repayment of related party advances, net	(20,000)	(67,000)
Repayment of convertible debt	(24,759)	(31,500)
Repayment of financing right-of-use liabilities		(18,395)
NET CASH PROVIDED BY FINANCING ACTIVITIES	4,545,241	1,697,624
NET CHANGE IN CASH	1,218,876	539,511
CASH, beginning of the year	560,407	20,896
CASH, end of the year	1,779,283	560,407
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest	20,582
Income taxes
Non-cash investing and financing activities:
Offering cost paid related to sale of Series E preferred stock	11,872
Series E preferred stock dividend and deemed dividend	2,006,120
Preferred stock issued upon debt conversions	217,215	125,000
Preferred stock issued upon conversion of accounts payable and accrued liabilities	459,153
Common stock issued for settlement of related party advances		53,450
Common stock issued for upon conversion of Series D-1 preferred stock	508,154
Common stock issued for upon conversion of Series D-2 preferred stock	4,122
Cash	675,928
Prepaid expense and other current assets	17,539
Accounts payable and other liabilities	(40,149)
Liabilities of discontinued operations	(406,662)
Net assets acquired	$ 246,656

Organization and Nature of Oper

Organization and Nature of Operations	12 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Nature of Operations	NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS Theralink Technologies, Inc., formerly OncBioMune Pharmaceuticals, Inc. (the “Company”), was a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary vaccine technology. On June 5, 2020, the Company acquired the assets (the “Asset Sale Transaction”) of Avant Diagnostics, Inc., a Nevada corporation established in 2009 (“Avant”) pursuant to the Asset Purchase Agreement dated May 12, 2020 between the Company and Avant (the “Asset Purchase Agreement”). Avant is a commercial-stage precision medicine and molecular data-generating company that focuses on the development and commercialization of a series of patented, proprietary data-generating assays that may provide important actionable information for physicians and patients, as well as biopharmaceutical companies, in the areas of oncology. Pursuant to the Asset Purchase Agreement, the Company acquired substantially all of the assets of Avant and assumed certain of its liabilities. Upon the terms and subject to the conditions of the Asset Purchase Agreement, Avant sold to the Company, all of Avant’s title and interest in, all of the assets, properties and rights of every kind and nature, whether real, personal or mixed, tangible or intangible (including goodwill), wherever located and whether existing or hereafter acquired, except for the specific excluded assets, which relate to, or are used or held for use in connection with, Avant’s business. The Company also hired Avant’s employees upon consummation of the Asset Sale Transaction. As consideration for the Asset Sale Transaction, the Company issued to Avant 1,000 shares of a newly created Series D-1 Preferred Stock which held 54.55% of all voting rights on an as-converted basis with the common stock. Upon the effectiveness of an increase of the Company’s authorized shares of common stock from 6,666,667 shares to 12,000,000,000 shares, all such shares of Series D-1 Preferred Stock issued to Avant automatically converted into 5,081,550,620 shares of the Company’s common stock. Avant possessed majority voting control of the Company immediately following the Asset Sale Transaction and controlled the Company’s Board of Directors after the termination of the ten-day waiting period required by Rule 14f-1 under the Exchange Act. Accordingly, the Asset Sale Transaction was accounted for, in substance, as an asset acquisition of the Company’s net assets by Avant and a recapitalization of Avant . On June 5, 2020, pursuant to the Asset Purchase Agreement, the Company; (i) entered into an employment agreement with Dr. Michael Ruxin to serve as the Company’s Chief Executive Officer, President and a director (see Note 10); (ii) entered into an employment agreement with Jeffery Busch to serve as the Company’s Chairman of the Board of Directors (see Note 10) and; (iii) appointed Yvonne Fors to its Board of Directors. On June 11, 2020, the Company filed a Certificate of Withdrawal of Designation with the Nevada Secretary of State terminating the designation, amount thereof, voting powers, preferences and relative participating, optional and other special rights of the shares of the preferred stock of the Company designated as Series B Preferred Stock (see Note 9). On August 14, 2020, the Board appointed Mr. Andrew Kucharchuk as Acting Chief Financial Officer of the Company, effective immediately. On August 14, 2020, the Board approved a change in the Company’s fiscal year end from December 31 to September 30, effective immediately for the current fiscal year, and for all subsequent years until such time as the Board resolves to amend such fiscal year end. The fiscal year has been changed to conform to the September 30 fiscal year end of Avant which is the historical registrant as a result of the Asset Sale Transaction consummated on June 5, 2020 and therefore, no transition report is required. On September 15, 2020, the Company filed a certificate of designation, preferences and rights of Series E Preferred Stock (the “Series E Certificate of Designation”) with the Nevada Secretary of the State of to designate 2,000 shares of its previously authorized preferred stock as Series E Preferred Stock, par value $0.0001 per share and a stated value of $2,000 per share. The Series E Certificate of Designation and its filing was approved by the Company’s board of directors without shareholder approval as provided for in the Company’s articles of incorporation and under Nevada law (see Note 9). On September 22, 2020, the Company filed with the Nevada Secretary of State an amendment to its Certificate of Incorporation to change its name from “OncBioMune Pharmaceutical, Inc.” to “Theralink Technologies, Inc.” and increase its authorized shares of common stock from 6,666,667 shares of common stock at $0.0001 per share par value to 12,000,000,000 shares of common stock at $0.0001 per share par value, effective September 24, 2020 (see Note 9). The 1,000 shares of Series D-1 Preferred stock and 4,121.6 shares of Series D-2 Preferred stock were automatically converted into 5,081,550,620 and 41,216,000 shares of common stock, respectively, upon increase of the authorized shares, pursuant to the Certificate of Designations of each (see Note 9). The change in authorized shares has been retroactively reflected in the accompanying consolidated balance sheets. On September 24, 2020, Andrew Kucharchuk resigned from his position as Acting Chief Financial Officer, effective immediately (see Note 8). Mr. Kucharchuk continues to serve as a director on the Company’s Board of Directors. On the same day, the Company appointed Thomas E. Chilcott, III, to serve as the Chief Financial Officer. On June 30, 2021, the Company filed a certificate of designation, preferences and rights of Series F Preferred Stock (the “Series F Certificate of Designation”), with the Nevada Secretary of State to designate 1,000 shares of its previously authorized preferred stock as Series F Preferred Stock, par value $0.0001 per share and a stated value of $2,000 per share. The Series F Certificate of Designation and its filing was approved by the Company’s board of directors without shareholder approval as provided for in the Company’s articles of incorporation and under Nevada law (see Note 12).

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America which present the consolidated financial statements of the Company and its wholly-owned inactive subsidiaries, OncBioMune, Inc. and OncBioMune Sub, Inc., as of September 30, 2020. Since there was no subsidiary, the financial statements are not consolidated as of September 30, 2019. All intercompany accounts and transactions have been eliminated in consolidation. Going Concern These consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying consolidated financial statements, the Company had net loss and net cash used in operations of $3,170,267 and $3,470,755, respectively, for the year ended September 30, 2020. Additionally, the Company had an accumulated deficit, stockholders’ deficit and working capital of $43,187,588, $307,595 and $877,234 at September 30, 2020. Management believes that these matters raise substantial doubt about the Company’s ability to continue as a going concern for twelve months from the issuance date of this report. The Company cannot provide assurance that it will ultimately achieve profitable operations or become cash flow positive or raise additional debt or equity capital. Additionally, the current capital resources are not adequate to continue operating and maintaining the business strategy for a period of twelve months from the issuance date of this report. The Company will seek to raise capital through additional debt and equity financings to fund its operations in the future. Although the Company has historically raised capital from sales of equity and from the issuance of promissory notes, there is no assurance that it will be able to continue to do so. If the Company is unable to raise additional capital or secure additional lending in the near future, management expects that the Company will need to curtail or cease operations. These consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The global pandemic COVID-19, otherwise referred to as the Coronavirus, could impair our ability to raise additional funding or make such funding more costly. The ongoing global pandemic has caused cessation of normal business operations and initially caused capital markets to decline sharply. This could make it more difficult for the Company to access capital. It is currently difficult to estimate with any certainty how long the pandemic and resulting curtailment of business will continue, and its effect on capital markets and the Company’s ability to raise funds is, accordingly, difficult to quantify. In addition, to the extent that any of the Company’s personnel or consultants are affected by the virus, this could cause delays or disruption in our planned research and development activities. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make judgments, assumptions, and estimates that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Management bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. Significant estimates during the years ended September 30, 2020 and 2019 include, but are not necessarily limited to, the valuation of assets and liabilities of discontinued operations, estimates of contingent liabilities, valuation of marketable securities, useful life of property and equipment, valuation of right-of-use (“ROU”) assets and lease liabilities, assumptions used in assessing impairment of long-lived assets, allowances for accounts receivable, estimates of current and deferred income taxes and deferred tax valuation allowances and the fair value of non-cash equity transactions. Additionally, the full impact of COVID-19 is unknown and cannot be reasonably estimated. However, the Company has made appropriate accounting estimates based on the facts and circumstances available as of the reporting date. To the extent there are material differences between the Company’s estimates and the actual results, the Company’s future consolidated results of operation will be affected. Fair Value of Financial Instruments and Fair Value Measurements FASB ASC 820 - Fair Value Measurements and Disclosures, defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. FASB ASC 820 requires disclosures about the fair value of all financial instruments, whether or not recognized, for financial statement purposes. Disclosures about the fair value of financial instruments are based on pertinent information available to the Company on September 30, 2020. Accordingly, the estimates presented in these financial statements are not necessarily indicative of the amounts that could be realized on disposition of the financial instruments. FASB ASC 820 specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The three levels of the fair value hierarchy are as follows: Level 1—Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. Level 2—Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. Level 3—Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. In August 2018, the FASB issued ASU 2018-13 —Fair Value Measurement (Topic 820): Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement Cash and Cash Equivalents The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. The Company’s investment policy is to preserve principal and maintain liquidity. The Company periodically monitors its positions with, and the credit quality of, the financial institutions with which it invests. The Company maintains its cash in banks and financial institutions that at times may exceed federally insured limits. There were cash balances in excess of FDIC insured levels of $1,538,951 and $310,407 as of September 30, 2020 and 2019, respectively. The Company has not experienced any losses in such accounts through September 30, 2020. Prepaid Assets Prepaid assets are carried at amortized cost. Significant prepaid assets as of September 30, 2020 and 2019 include, but are not necessarily limited to, prepaid insurance, prepaid consulting fees, prepaid equipment maintenance fee and retainers for professional services. Laboratory Supplies Laboratory supplies are normally consumed within a year from purchase and any unused laboratory supplies are classified as current asset and reflected in the accompanying consolidated balance sheet as laboratory supplies. Property and Equipment Fixed assets are stated at cost and depreciated using the straight-line method over their estimated useful lives, which range from three to five years. Leasehold improvements are depreciated over the shorter of the useful life or lease term including scheduled renewal terms. Maintenance and repairs are charged to expense as incurred. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the year of disposition. The Company examines the possibility of decreases in the value of these assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. Impairment of Long-Lived Assets In accordance with ASC Topic 360, the Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable, or at least annually. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value. Stock-Based Compensation Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. Pursuant to ASC 505-50 - Equity-Based Payments to Non-Employees, all share-based payments to non-employees, including grants of stock options, were recognized in the consolidated financial statements as compensation expense over the service period of the consulting arrangement or until performance conditions are expected to be met. Using a Black Scholes valuation model, the Company periodically reassessed the fair value of non-employee options until service conditions are met, which generally aligns with the vesting period of the options, and the Company adjusts the expense recognized in the consolidated financial statements accordingly. In June 2018, the FASB issued ASU No. 2018-07, Improvements to Nonemployee Share-Based Payment Accounting, which simplifies several aspects of the accounting for nonemployee share-based payment transactions by expanding the scope of the stock-based compensation guidance in ASC 718 to include share-based payment transactions for acquiring goods and services from non-employees. ASU No. 2018-07 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods. Early adoption is permitted, but entities may not adopt prior to adopting the new revenue recognition guidance in ASC 606. The Company early adopted ASU No. 2018-07 during the period September 30, 2018, and the adoption did not have any impact on its consolidated financial statements. Revenue Recognition In May 2014, FASB issued an Accounting Standards Update, ASU 2014-09, establishing ASC 606 - Revenue from Contracts with Customers. ASU 2014-09, as amended by subsequent ASUs on the topic, establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard, which is effective for interim and annual reporting periods in fiscal years that begin after December 15, 2017, requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures. The Company adopted this standard during the fiscal year ended September 30, 2018 using the modified retrospective approach, which requires applying the new standard to all existing contracts not yet completed as of the effective date and recording a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. Based on an evaluation of the impact ASU 2014-09 will have on the Company’s sources of revenue, the Company has concluded that ASU 2014-09 did not have any impact on the process for, timing of, and presentation and disclosure of revenue recognition from customers and there was no cumulative effect adjustment. The Company provides research and development support to biopharmaceutical companies to assist their drug development programs. The services provided by the Company are performance obligations under services contracts. These contracts are completed over time and may lead to deferred revenue for services not completed at the end of a period. Management reviews the completion status of all jobs monthly to determine the appropriate amount of revenue to recognize. Cost of Revenue The cost of revenue consists of cost of labor, supplies and materials. Accounts Receivable and Allowance for Doubtful Accounts Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis and do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. Concentrations Concentration of Revenues During the year ended September 30, 2020, the Company generated total revenue of $181,229 of which 56% and 44% were from two of the Company’s customers. During the year ended September 30, 2019, the Company did not have any revenue. Basic and Diluted Loss Per Share Pursuant to ASC 260-10-45, basic loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the periods presented. Diluted loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. Potentially dilutive common shares consist of common stock issuable for stock options and warrants (using the treasury stock method), convertible notes and common stock issuable. These common stock equivalents may be dilutive in the future. The following potentially dilutive equity securities outstanding as of September 30, 2020 and 2019 were not included in the computation of dilutive loss per common share because the effect would have been anti-dilutive: September 30, 2020 2019 Stock warrants 856,674,588 — Series C-1 preferred stock 445,301,289 — Series C-2 preferred stock 733,542,619 — Series D-1 preferred stock — 4,392,557,509 Series E preferred stock 533,333,333 — 2,568,851,829 4,392,557,509 Income Taxes The Company accounts for income tax using the liability method prescribed by ASC 740 - Income Taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company follows the accounting guidance for uncertainty in income taxes using the provisions of ASC 740 “Income Taxes Related Parties Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal with if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. Leases In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, Leases On January 1, 2019, the Company adopted ASU No. 2016-02, applying the package of practical expedients to leases that commenced before the effective date whereby the Company elected to not reassess the following: (i) whether any expired or existing contracts contain leases and; (ii) initial direct costs for any existing leases. For contracts entered into on or after the effective date, at the inception of a contract the Company assessed whether the contract is, or contains, a lease. The Company’s assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether the Company has the right to direct the use of the asset. The Company will allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments. The Company has elected not to recognize right-of-use (“ROU”) assets and lease liabilities for short-term leases that have a term of 12 months or less. Operating and financing lease ROU assets represents the right to use the leased asset for the lease term. Operating and financing lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. As most leases do not provide an implicit rate, the Company use an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general and administrative expenses in the consolidated statements of operations. Reclassifications On the consolidated balance sheet as of September 30, 2019, (i) $4,000 of accounts receivable has been reclassified to other receivables and (ii) $70,000 of accrued liabilities has been reclassified to accrued director compensation, to conform to the September 30, 2020 consolidated balance sheet presentation. These reclassifications do not have a significant impact on the reported financial position and does not impact the results of operations or cash flows. Recent Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06— Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and edging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”) Debt with Conversion and Other Options 1. Add a disclosure objective 2. Add information about events or conditions that occur during the reporting period that cause conversion contingencies to be met or conversion terms to be significantly changed 3. Add information on which party controls the conversion rights 4. Align disclosure requirements for contingently convertible instruments with disclosure requirements for other convertible instruments 5. Require that existing fair value disclosures in Topic 825, Financial Instruments, be provided at the individual convertible instrument level rather than in the aggregate. Additionally, for convertible debt instruments with substantial premiums accounted for as paid-in capital, amendments in ASU 2020-06 added disclosures about (1) the fair value amount and the level of fair value hierarchy of the entire instrument for public business entities and (2) the premium amount recorded as paid-in capital. The amendments in ASU 2020-06 are effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Entities should adopt the guidance as of the beginning of its annual fiscal year and are allowed to adopt the guidance through either a modified retrospective method of transition or a fully retrospective method of transition. In applying the modified retrospective method, entities should apply the guidance to transactions outstanding as of the beginning of the fiscal year in which the amendments are adopted. Transactions that were settled (or expired) during prior reporting periods are unaffected. The cumulative effect of the change should be recognized as an adjustment to the opening balance of retained earnings at the date of adoption. If an entity elects the fully retrospective method of transition, the cumulative effect of the change should be recognized as an adjustment to the opening balance of retained earnings in the first comparative period presented. The Company is evaluating the impact of the revised guidance and believes that it will not have a significant impact on its consolidated financial statements. Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the Company’s consolidated financial statements.

Asset Sale and Recapitalization

Asset Sale and Recapitalization Transaction	12 Months Ended
	Sep. 30, 2020
Business Combination and Asset Acquisition [Abstract]
Asset Sale and Recapitalization Transaction	NOTE 3 – ASSET SALE AND RECAPITALIZATION TRANSACTION Avant provided personalized medical data through its Theralink assays, initially for breast cancer, to assist treating physicians in a data-driven process for treatment decision support and to help enable predictive biomarker-based patient therapy selection. Avant was a developer of phosphoproteomic technologies for measuring the activation state of therapeutic targets and signaling pathways, a key metric for biopharmaceuticals, with applications across multiple cancer types, including breast, non-small cell lung, GI, gynecologic and pancreatic, among others. On June 5, 2020, the Company closed the Asset Purchase Agreement entered into with Avant on May 12, 2020. Pursuant to the Asset Purchase Agreement, the Company acquired substantially all of the assets and business of Avant and assumed certain of its liabilities in the Asset Sale Transaction. Upon the terms and subject to the conditions of the Asset Purchase Agreement, Avant sold to the Company, all of Avant’s title and interest in all of the assets, properties and rights of every kind and nature, whether real, personal or mixed, tangible or intangible (including goodwill), wherever located and whether existing or hereafter acquired, except for the specific excluded assets, which relate to, or are used or held for use in connection with, Avant’s business. The Company also hired Avant’s employees upon consummation of the Asset Sale Transaction. As consideration for the Asset Sale Transaction, Avant was issued 1,000 shares of a newly created Series D-1 Preferred Stock which held 54.55% of all voting rights on an as-converted basis with the common stock. Upon the increase of the Company’s authorized shares of common stock from 6,666,667 shares to 12,000,000,000 shares effective September 24, 2020, all such shares of Series D-1 Preferred Stock issued to Avant automatically converted into 5,081,550,620 shares of the Company’s common stock. Avant possessed majority voting control of the Company immediately following the Asset Sale Transaction and controlled the Company’s Board of Directors after the termination of the ten-day waiting period required by Rule 14f-1 under the Exchange Act. Accordingly, the Asset Sale Transaction was accounted for, in substance, as an asset acquisition of the Company’s net assets by Avant and a recapitalization of Avant as discussed in detail below under “Accounting for the Asset Sale Transaction”. On June 5, 2020, pursuant to the Asset Purchase Agreement, the Company; (i) entered into an employment agreement with Dr. Michael Ruxin to serve as the Company’s Chief Executive Officer, President and a director (see Note 10); (ii) entered into an employment agreement with Jeffery Busch to serve as the Company’s Chairman of the Board of Directors (see Note 10) and (iii) appointed Yvonne Fors to its Board of Directors. Accounting for the Asset Sale Transaction The Asset Sale Transaction was accounted for, in substance, as an asset acquisition of the Company’s net assets by Avant and a recapitalization of Avant as the Company did not meet the definition of a business under the framework provided under ASC 805-10-55-5D through 55-6 - Business Combination The cost of the Asset Sale Transaction was determined in accordance with ASC 805-50-30-1 through 30-2 Business Combinations In accordance with ASC 805-50-30-1, the fair value of the 1,000 shares of Series D-1 Preferred Stock, issued as consideration, was determined to be $246,656 which was the book value of the Company’s net assets that were acquired by Avant as of the closing date of the transaction. The cost of the Asset Sale Transaction was allocated to the acquired assets and assumed liabilities based on their estimated fair values. The following assets and liabilities were assumed in the transaction: Cash $ 675,928 Prepaid expense and other current assets 17,539 Total assets acquired 693,467 Accounts payable and other liabilities (40,149 ) Liabilities of discontinued operations (406,662 ) Total liabilities assumed (446,811 ) Net assets acquired $ 246,656 The functional currency of the former subsidiaries which operated in Mexico is the Mexican Peso (“Peso”). The assumed liabilities of discontinued operations were translated to U.S. dollars using period end rates of exchange for liabilities. Net gains and losses resulting from foreign exchange transactions are reflected as unrealized gain (loss) on exchange rate in the consolidated statements of operations and is a non-cash loss. As a result of foreign currency translations, which are a non-cash adjustment, we reported an unrealized gain on exchange rate, net of $49,202 during the year ended September 30, 2020. During the year ended September 30, 2020, $158,852 of the assumed liabilities of discontinued operations were written-off, in accordance with ASC 405-20-40-1b, and were recorded as a gain on debt extinguishment on the accompanying consolidated statement of operations.

Marketable Securities

Marketable Securities	12 Months Ended
	Sep. 30, 2020
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	NOTE 4 – MARKETABLE SECURITIES During the fiscal year ended 2017, the Company acquired 1,000,000 shares of common stock of Amarantus BioScience Holdings, Inc. (“AMBS”) with a fair value of $40,980. The AMBS common stock is recorded as marketable securities in the accompanying consolidated balance sheets and its fair value is adjusted every reporting period and the change in fair value is recorded in the consolidated statements of operations as unrealized gain or (loss) on marketable securities. During the years ended September 30, 2020 and 2019, the Company recorded $6,900 and $15,800, respectively, of unrealized loss on marketable securities. As of September 30, 2020 and 2019, the fair value of these shares were $11,100 and $18,000, respectively.

Property and Equipment

Property and Equipment	12 Months Ended
	Sep. 30, 2020
Property, Plant and Equipment [Abstract]
Property and Equipment	NOTE 5 – PROPERTY AND EQUIPMENT Property and equipment are recorded at cost and once placed in service, are depreciated on the straight-line method over their estimated useful lives. Leasehold improvements are accreted over the shorter of the estimated economic life or related lease terms. Fixed assets consist of the following: Estimated Useful Life in Years September 30, 2020 September 30, 2019 Laboratory equipment 5 $ 404,628 $ 103,247 Furniture 5 13,367 — Leasehold improvements 5 347,809 216,984 Computer equipment 3 53,060 1,329 818,864 321,560 Less accumulated depreciation (74,042 ) (22,650 ) Property and equipment, net $ 744,822 $ 298,910 For the years ended September 30, 2020 and 2019, depreciation expense related to property and equipment amounted to $51,392 and $20,160, respectively.

Debt

Debt	12 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Debt	NOTE 6 – DEBT Convertible Debt On May 25, 2018, the Company entered into an exchange Agreement (the “Coastal Exchange Agreement”) with Coastal Investment Partners, LLC (“Coastal”). Pursuant to the terms of the Coastal Exchange Agreement, the Company agreed to exchange the principal amount due under the convertible promissory note dated July 6, 2016 plus accrued but unpaid interest, default penalties and other amounts due and payable under such notes, which was $305,664 as of the Effective Date (the “Coastal Notes”) in exchange for (i) 192,832 shares of Series A Preferred Stock having an aggregate value of $192,832 and (ii) the issuance of a new convertible promissory note due eighteen (18) months from the Effective Date in the aggregate principal amount of $192,832 (the “New Coastal Note”). The New Coastal Note shall bear interest at 8% per annum and is convertible into shares of the Company’s common stock at $0.015 per share, subject to adjustment. Coastal has contractually agreed to restrict their ability to convert the New Coastal Note such that the number of shares of the Company common stock held by them and their affiliates after such conversion does not exceed 9.99% of the Company’s then issued and outstanding shares of common stock. In connection with the Coastal Exchange Agreement, Coastal agreed to waive the defaults and breaches that have resulted on or prior to the Effective Date as well as any penalties, interest or other amounts that may have accrued under the Coastal Notes after March 31, 2018. In addition, Coastal entered into a termination agreement with the Company pursuant to which as of the Effective Date, (i) the securities purchase agreements and pledge agreements entered into with Coastal (the “Coastal Prior Agreements”) were terminated in their entirety and shall have no further force or effect, (ii) the security interests granted by the pledge agreement were terminated and shall have no further force or effect and (iii) neither party shall have any further rights or obligations under the Coastal Prior Agreements. Coastal also authorized the Company or its representatives to take all actions as they determine in their sole discretion to discharge and release any and all security interests, pledges, liens, and other encumbrances held by it on the Company’s assets. As of September 30, 2019, the New Coastal Note had outstanding principal of $192,832 and accrued interest payable of $20,783 which is recorded as accrued liabilities in the accompanying balance sheets. During the year ended September 30, 2020, the lender converted the principal balance of $192,832 and accrued interest of $24,383 into shares of Series D-1 preferred stock. As of September 30, 2020, the Coastal Notes had no outstanding balance. This note was a legal liability of Avant. It was settled prior to the asset acquisition described in footnote 3. On May 25, 2018, the Company entered into an exchange agreement (the “Black Mountain Exchange Agreement”) with Black Mountain Equity Partners LLC (“Black Mountain”). Pursuant to the terms of the Black Mountain Exchange Agreement, the Company agreed to exchange the principal amount due under the convertible promissory note dated November 11, 2016 (the “Black Mountain Note”) in exchange for the issuance of a new promissory note due twelve (12) months from the Effective Date in the aggregate principal amount of $25,000 (which includes a prepayment amount of $5,000 made on the Effective Date) (the “New Black Mountain Note”). The New Black Mountain Note shall bear interest at 12% per annum and has mandatory payments of $5,000 every 90 days until paid in full. In connection with the Black Mountain Exchange Agreement, Black Mountain agreed to waive the defaults and breaches that have resulted on or prior to the Effective Date as well as any penalties, interest or other amounts that may have accrued under the Black Mountain Note after March 31, 2018. During the fiscal year ended 2018, the Company paid $10,000 of the principal balance. During the fiscal year ended 2019, the Company paid $7,500 of the principal. As of September 30, 2019, the Black Mountain Note had outstanding principal of $7,500. During the year ended September 30, 2020, the Company repaid the outstanding balance. As of September 30, 2020, the Black Mountain Note had no outstanding balance. This note was a legal liability of Avant. It was settled prior to the asset acquisition described in footnote 3. On May 25, 2018, the Company entered into an exchange agreement with a certain investor for the issuance of new promissory note due twenty-four (24) months from the Effective Date in the aggregate principal amount of $47,259 (the “New 2016 Investor Note”). The New 2016 Investor Note shall bear interest at 12% per annum and has mandatory payments of $2,000 every 30 days until paid in full starting June 25, 2018. In connection with the 2018 Investor Exchange Agreement, the 2016 Investor has agreed to waive the defaults and breaches that have resulted on or prior to the Effective Date as well as any penalties, interest or other amounts that may have accrued under the 2016 Note after March 31, 2018. During the fiscal year ended 2018, the Company paid $6,000 of the principal balance. During the fiscal year ended 2019, the Company paid $24,000 of the principal. As of September 30, 2019, the New 2016 Investor Note had outstanding principal of $17,259 and accrued interest payable of $5,981 which is recorded as accrued liabilities in the accompanying balance sheets. During the year ended September 30, 2020, the Company repaid the outstanding principal of $17,259 and recognized a gain on debt extinguishment related to the forgiveness for the accrued interest in the amount of $6,587. As of September 30, 2020, the New 2016 Investor Note had no outstanding balance. This note was a legal liability of Avant. It was settled prior to the asset acquisition described in footnote 3. Notes Payable On October 28, 2016, the Company entered into a note agreement (the “Note I”) for the sale of the Company’s convertible note with a principal amount of $20,000. The Company received $20,000 in proceeds from the sale. Note I bears an interest rate of 12% per year (which interest rate shall be increased to 18% per year upon the occurrence of an Event of Default (as defined in Note I)), matured on April 28, 2017 and the principal and interest are convertible at any time at a conversion price equal to the lower of $0.25 or closing price on the date of the conversion, provided, however, that if an event of default has occurred, regardless of whether such Event of Default has been cured or remains ongoing, the Note I shall be convertible at 65% of the lowest VWAP , as reported on the OTCQB or other principal trading market, during the prior twenty trading days (the “Default Conversion Price”). The purchaser may not convert the Note to the extent that such conversion would result in beneficial ownership by a purchaser and its affiliates of more than 4.99% of the Company’s issued and outstanding common stock. Note I may be prepaid, in whole or in part, at any time upon five-days written notice to the holder at an amount equal to (i) 110% of the outstanding principal prepayment amount during the first 30 days after the execution of Note I; (ii) 115% of the outstanding principal prepayment amount if paid between the 31 st th st th st On July 28, 2017, the Company entered into an Exchange Agreement, with the holder to exchange Note I dated October 28, 2016, with a principal balance of $20,000 and a maturity date of April 28, 2017, with a new note (“Exchange Note I”). Note I defaulted on the maturity date for non-payment. The Exchange Note I had a purchase price of $20,000, net of $5,600 Original Issue Discount for an aggregate principal amount of $25,600. The Exchange Note I bears an interest rate of 10% per year (which shall be increased to 18% per year upon the occurrence of an Event of Default (as defined in Exchange Note I)), maturity date of July 28, 2019 and convertible at any time at a fix conversion price equal to $0.06 per share. During the fiscal year ended September 30, 2018, the Company failed to meet the requirements set forth in the Exchange Agreement which resulted in the Exchange Agreement being considered null and void by both parties whereas the original Note I remains in full force and effect. As of September 30, 2019, the Note I is in default and had outstanding principal of $20,000 and accrued interest payable of $8,420 which is recorded as accrued liabilities in the accompanying balance sheet. During the year ended September 30, 2020, as a result of the Asset sale and recapitalization transaction (see Note 3), and this promissory note liability not being assumed in the transaction (see Note 10), the Company reclassified the Note I outstanding principal of $20,000 and accrued interest of $12,020 to contingent liabilities for a total amount of $32,020. On October 28, 2016, the Company entered into a note agreement (the “Note II”) for the sale of the Company’s convertible note for a principal amount of $20,000. The Company received $20,000 in proceeds from the sale. Note II bears an interest rate of 12% per year (which interest rate shall be increased to 18% per year upon the occurrence of an Event of Default (as defined in Note II)), matured on April 28, 2017 and the principal and interest are convertible at any time at a conversion price equal to the lower of $0.25 or closing price on the date of the conversion, provided, however, that if an event of default has occurred, regardless of whether such Event of Default has been cured or remains ongoing, Note II shall be convertible at 65% of the lowest VWAP, as reported on the OTCQB or other principal trading market, during the prior twenty trading days (the “Default Conversion Price”). The purchaser may not convert Note II to the extent that such conversion would result in beneficial ownership by a purchaser and its affiliates of more than 4.99% of the Company’s issued and outstanding common stock. Note II may be prepaid, in whole or in part, at any time upon five-days written notice to the holder at an amount equal to (i) 110% of the outstanding principal prepayment amount during the first 30 days after the execution of Note II; (ii) 115% of the outstanding principal prepayment amount if paid between the 31 st th st th st On July 28, 2017, the Company entered into an Exchange Agreement, with the holder to exchange Note II dated October 28, 2016, with a principal balance of $20,000 and a maturity date of April 28, 2017, with a new note (“Exchange Note II”). Note II defaulted on the maturity date for non-payment. The Exchange Note II had a purchase price of $20,000, net of $5,600 Original Issue Discount for an aggregate principal amount of $25,600. The Exchange Note II bears an interest rate of 10% per year (which shall be increased to 18% per year upon the occurrence of an Event of Default (as defined in Exchange Note II)), maturity date of July 28, 2019 and convertible at any time at a fix conversion price equal to $0.06 per share. During the fiscal year ended September 30, 2018, the Company failed to meet the requirements set forth in the Exchange Agreement which resulted in the Exchange Agreement being considered null and void by both parties whereas the original Note II remains in full force and effect. As of September 30, 2019, the Note II is in default and had outstanding principal of $20,000 and accrued interest payable of $8,420 which is recorded as accrued liabilities in the accompanying balance sheet. During the year ended September 30, 2020, as a result of the Asset sale and recapitalization transaction (see Note 3) and this promissory note liability not being assumed in the transaction (see Note 10), the Company reclassified the Note II outstanding principal of $20,000 and accrued interest of $12,020 to contingent liabilities for a total amount of $32,020. As of September 30, 2020, the contingent liabilities consisted of two notes payables, discussed above, with a total outstanding principal balance of $40,000 and accrued interest payable of $24,040 for a total amount of $64,040 as of September 30, 2020. In September 2017, the Company entered into a loan agreement with a third-party investor (the “Loan”). Pursuant to the loan agreement, the Company borrowed the principal amount of $1,000. The Loan bears an annual interest rate of 33.3%, is unsecured and in default due to non-payment of the balance pursuant to the repayment terms. As of September 30, 2020, the loan had principal and accrued interest balances of $1,000 and $1,022, respectively

Lease Liabilities and Right of

Lease Liabilities and Right of Use Assets	12 Months Ended
	Sep. 30, 2020
Leases [Abstract]
Lease Liabilities and Right of Use Assets	NOTE 7 – LEASE LIABILITIES AND RIGHT OF USE ASSETS Financing Lease Right-of-Use (“ROU”) Assets and Financing Lease Liabilities Effective November 2018, the Company entered into a financing agreement with the first lessor to finance the purchase of equipment. Pursuant to the financing agreement, the Company shall make a monthly payment of $379 for a period of 60 months commencing in November 2018 through October 2023. At the effective date of the financing agreement, the Company recorded a financing lease payable of $16,064. Effective November 2018, the Company entered into a financing agreement with the second lessor to finance the purchase of equipment. Pursuant to the financing agreement, the Company shall make a monthly payment of $1,439 for a period of 60 months commencing in November 2018 through October 2023. At the effective date of the financing agreement, the Company recorded a financing lease payable of $62,394. Effective March 2019, the Company entered into a financing agreement with the third lessor to finance the purchase of equipment. Pursuant to the financing agreement, the Company shall make a monthly payment of $1,496 for a period of 60 months commencing in March 2019 through April 2024. At the effective date of the financing agreement, the Company recorded a financing lease payable of $64,940. Effective August 2019, the Company entered into a financing agreement with the fourth lessor to finance the purchase of equipment. Pursuant to the financing agreement, the Company shall make a monthly payment of $397 for a period of 60 months commencing in August 2019 through August 2024. At the effective date of the financing agreement, the Company recorded a financing lease payable of $19,622. Effective January 2020, the Company entered into a financing agreement with the fifth lessor to finance the purchase of equipment. Pursuant to the financing agreement, the Company shall make a monthly payment of $1,395 for a period of 60 months commencing in January 2020 through December 2024. At the effective date of the financing agreement, the Company recorded a financing lease payable of $68,821. The significant assumption used to determine the present value of the financing lease payables was a discount rate which ranged from between 8% and 15% based on the Company’s estimated effective rate pursuant to the financing agreements. Financing lease right-of-use assets (“Financing ROU”) is summarized below: September 30, 2020 2019 Financing ROU assets $ 231,841 $ 231,841 Less accumulated depreciation (74,150 ) (27,782 ) Balance of Financing ROU assets $ 157,691 $ 204,059 For the years ended September 30, 2020 and 2019, depreciation expense related to Financing ROU assets amounted to $46,368 and $27,380, respectively. Financing lease liability related to the Financing ROU assets is summarized below: September 30, 2020 2019 Financing lease payables for equipment $ 231,841 $ 231,841 Total financing lease payables 231,841 231,841 Payments of financing lease liabilities (53,491 ) (18,395 ) Total 178,350 213,446 Less: short term portion (42,234 ) (35,096 ) Long term portion $ 136,116 $ 178,350 Future minimum lease payments under the financing lease agreements at September 30, 2020 are as follows: Years ending September 30, Amount 2021 $ 61,266 2022 61,266 2023 53,787 2024 40,875 2025 4,185 Total minimum financing lease payments 221,379 Less: discount to fair value (43,029 ) Total financing lease payable at September 30, 2020 $ 178,350 Operating Lease Right-of-Use (“ROU”) Asset and Operating Lease Liabilities In December 2019, the Company entered into a lease agreement for its corporate and laboratory facility in Golden, Colorado. The lease is for a period of 60 months, with an option to extend, commencing in February 2020 and expiring in February 2025. Pursuant to the lease agreement, the lease requires the Company to pay a monthly base rent of; (i) $4,878 in the first year; (ii) $5,026 in the second year; (iii) $5,179 in the third year; (iv) $5,335 in the fourth year and; (v) $5,495 in the fifth year, plus a pro rata share of operating expenses beginning February 2020. In adopting ASC Topic 842, Leases (Topic 842), the Company has elected the ‘package of practical expedients’, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs (see Note 2). In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 month or less. At the effective date of the lease, the Company recorded right-of-use assets and lease liabilities of $231,337. For the year ended September 30, 2020, lease costs amounted to $34,147 which included base lease costs of $18,501 and other expenses of $15,646, all of which were expensed during the period and included in general and administrative expenses on the accompanying consolidated statements of operations. The significant assumption used to determine the present value of the lease liability was a discount rate of 12% which was based on the Company’s estimated incremental borrowing rate. Operating right-of-use asset (“ROU”) is summarized below: September 30, 2020 Operating office lease $ 231,337 Less accumulated reduction (25,134 ) Balance of ROU asset as of September 30, 2020 $ 206,203 Operating lease liability related to the ROU asset is summarized below: September 30, 2020 Operating office lease $ 231,337 Total lease liabilities 231,337 Reduction of lease liability (18,501 ) Total 212,836 Less: short term portion as of September 30, 2020 (35,943 ) Long term portion as of September 30, 2020 $ 176,893 Future base lease payments under the non-cancellable operating lease at September 30, 2020 are as follows: Years ending September 30, Amount 2021 $ 59,576 2022 61,382 2023 63,236 2024 65,137 2025 27,474 Total minimum non-cancellable operating lease payments 276,805 Less: discount to fair value (63,969 ) Total lease liability at September 30, 2020 $ 212,836

Related-Party Transactions

Related-Party Transactions	12 Months Ended
	Sep. 30, 2020
Related Party Transactions [Abstract]
Related-Party Transactions	NOTE 8 – RELATED-PARTY TRANSACTIONS On October 17, 2018, the Company entered into a securities purchase agreement with Henry Cole, a prior director of the Company, pursuant to which the Company sold shares of its Series D-1 Preferred stock for aggregate gross proceeds of $20,000. On October 26, 2018, the Company entered into a securities purchase agreement with Dr. Rajesh Shrotriya, a prior director of the Company, pursuant to which the Company sold shares of its Series D-1 Preferred stock for aggregate gross proceeds of $100,000. On December 31, 2018, the Company entered into a securities purchase agreement with Dr. Rajesh Shrotriya, a prior director of the Company, pursuant to which the Company sold shares of its Series D-1 Preferred stock for aggregate gross proceeds of $50,000. On February 8, 2019, the Company entered into a securities purchase agreement with Infusion 51a, LP, represented by Jeffrey Stephens, a director of the Company, pursuant to which the Company sold shares of its Series D-1 Preferred stock for aggregate gross proceeds of $35,000. On July 3, 2019, the Company entered into a securities purchase agreement with Matthew Schwartz, a prior director of the Company, pursuant to which the Company sold shares of its Series D-1 Preferred stock for aggregate gross proceeds of $250,000. Pursuant to the asset sale and recapitalization transaction (see Note 3), an aggregate of 1 share of the Series D-1 Preferred stock was issued for the above transactions totalling $455,000 (see Note 9). On June 5, 2020, the Company entered into a consulting agreement with Mr. Kucharchuk, a member of the Board of Directors, to serve as a strategic advisor to the Company’s Chief Executive Officer. The agreement shall be effective for a period of six-months, commencing on June 5, 2020 (see Note 3). On August 14,2020, Mr. Kucharchuk was appointed as the acting Chief Financial Officer. Thereafter, the agreement shall only renew on a month-to-month basis by mutual agreement of the parties. Pursuant to the agreement, Mr. Kucharchuk shall receive compensation in the amount of $15,000 per month. Mr. Kucharchuk resigned as Company’s Chief Financial Officer in September 2020 (see Note 1). During the year ended September 30, 2020, a $160,000 outstanding balance owed for consulting fee – related party was converted into 0.24 shares of Series D-1 Preferred. During the year ended September 30, 2020, the Company repaid an outstanding $20,000 advance to a related parties. As of September 30, 2020, there were no outstanding balances due to related parties. At September 30, 2020 and 2019, amounts due to related parties consisted of the following: September 30, 2020 2019 Consulting fee – related party $ — $ 160,000 Advances from related parties — 20,000 Total $ — $ 180,000 Consulting fees – related party consisted of consulting fees for management related services provided by an affiliate entity and advances from Dr. Ruxin to fund the Company’s working capital.

Stockholders' Deficit

Stockholders' Deficit	12 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Stockholders' Deficit	NOTE 9 – STOCKHOLDERS’ DEFICIT Shares Authorized On September 22, 2020, the Company filed with the Nevada Secretary of State an amendment to its Certificate of Incorporation to change its name from “OncBioMune Pharmaceutical, Inc.” to “Theralink Technologies, Inc.” and increase its authorized shares of common stock from 6,666,667 shares of common stock at $0.0001 per share par value to 12,000,000,000 shares of common stock at $0.0001 per share par value, effective September 24, 2020 (see Note 1). Series A Preferred Stock On August 20, 2015, the Company filed the Certificate of Designation with the Nevada Secretary of State, designating 1,333 shares of the authorized 26,667 Preferred Stock as Series A Preferred Stock. Each holder of Series A Preferred Stock is entitled to 500 votes for each share of Series A Preferred Stock held as of the applicable date on any matter that is submitted to a vote or for the consent of the stockholders of the Company. The holders of Series A Preferred Stock shall have no special voting rights and their consent is not required (except to the extent they are entitled to vote with holders of Common Stock as set forth herein) for the taking of any corporate action. On June 5, 2020, pursuant to the asset sale transaction and recapitalization (see Note 3), 667 shares of Series A were deemed to have been issued. As of September 30, 2020, there were 667 shares of the Company’s Series A Preferred Stock issued and outstanding held by a former member of the Board of Directors. Series B Preferred Stock On March 7, 2017, the Company filed a Certificate of Designation, Preferences and Rights of Series B Preferred Stock (the “Series B Certificate of Designation”) with the Nevada Secretary of State to designate 10,523 shares of its previously authorized preferred stock as Series B Preferred Stock, par value $0.0001 per share and a stated value of $0.0001 per share. The Series B Certificate of Designation and its filing was approved by the Company’s board of directors without shareholder approval as provided for in the Company’s articles of incorporation and under Nevada law. The holders of shares of Series B Preferred Stock were entitled to dividends or distributions share for share with the holders of the common stock, if, as and when declared from time to time by the Board of Directors. On June 11, 2020, the Company filed a Certificate of Withdrawal of Designation with the Nevada Secretary of State terminating the designation, amount thereof, voting powers, preferences and relative participating, optional and other special rights of the shares of the preferred stock of the Company designated as Series B Preferred Stock (see Note 1). As of September 30, 2020, there were no shares of the Company’s Series B Preferred Stock issued and outstanding. Series C-1 Preferred Stock On May 18, 2020, the Company filed a certificate of designation, preferences and rights of Series C-1 Preferred Stock (the “Series C-1 Certificate of Designation”), as amended on June 9, 2021, with the Nevada Secretary of State to designate 3,000 shares of its previously authorized preferred stock as Series C-1 Preferred Stock, par value $0.0001 per share and a stated value of $4,128.42 per share. The Series C-1 Certificate of Designation and its filing was approved by the Company’s board of directors without shareholder approval as provided for in the Company’s articles of incorporation and under Nevada law. The holders of shares of Series C-1 Preferred Stock have the following preferences and rights: On June 9, 2021, the Company filed an Amendment (the “CoD Amendment”) to the Series C-1 Certificate of Designation with the Nevada Secretary of State. The filing of the CoD Amendment was approved by the Board on June 8, 2021, and by the holders of the majority of the outstanding shares of Series C-1 Preferred Stock on June 8, 2021. The CoD Amendment sets the triggering price for the anti-dilution price protection at $0.00275 per share, the same price as the Series C-2 Certificate of Designation. All other terms of the Series C-1 Certificate of Designation remain unchanged and in full force and effect. ● Holders of shares of Series C-1 Preferred Stock are entitled to dividends or distributions on each share on an “as converted” into common stock basis, if, as and when declared from time to time by the Board of Directors. ● Each share of Series C-1 Preferred Stock is convertible into shares of common stock any time after the Initial Issuance Date at a conversion price of $0.0275 per share. The number of shares of common stock issuable upon conversion shall be determined by dividing (x) (y) ● In the event the Company issues or sells any securities including options or convertible securities, except for any Exempt Issuance (as defined in the Series C-1 Certificate of Designation), at a price of or with an exercise price or conversion price of less than $0.0275 per share (see amendment discussed above), then upon such issuance or sale, the Series C-1 Preferred Stock conversion price shall be reduced to the sale price, the exercise price or conversion price of the securities sold. In addition, these preferred shareholders have the right to participate in future equity offerings from the company for twenty-four months from the effective date. ● In the event of the voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up of the Company, the holders of the Series C-1 Preferred Stock shall be entitled to receive, in cash out of the assets of the Company, whether from capital or from earnings available for distribution to its stockholders (“Liquidation Funds”) before any amount shall be paid to the holders of any shares of Junior Stock, but pari passu with any Parity Stock (as defined in the Series C-1 Certificate of Designation) then outstanding, an amount per shares of the Series C-1 Preferred Stock equal to the greater of (A) the conversion amount thereof on the date of such payment or (B) the amount per share such holder of Series C-1 Preferred Stock would receive if such holder converted such Series C-1 into common stock immediately prior to the date of the payment, provided that if the Liquidation Funds are insufficient to pay the full amount due to the holders of Series C-1 Preferred Stock and holders of the shares of Parity Stock, then each holder of Series C-1 Preferred Stock and each holder of Parity Stock shall receive a percentage of the Liquidation Funds equal to the full amount of the Liquidation Funds payable to such holder of Series C-1 Preferred Stock and such holder of the Parity Stock as a liquidation preference, in accordance with their respective certificate of designation (or equivalent), as a percentage of the full amount of Liquidation Funds payable to all holders of Series C-1 Preferred Stock and all holders of Parity Stock. On June 5, 2020, pursuant to the asset sale and recapitalization transaction (see Note 3), 2,966.2212 shares of Series C-1 Preferred Stock was deemed to have been issued. As of September 30, 2020, the Company had 2,966.2212 shares of Series C-1 Preferred Stock issued and outstanding. Series C-2 Preferred Stock On May 18, 2020, the Company filed a certificate of designation, preferences and rights of Series C-2 Preferred Stock (the “Series C-2 Certificate of Designation”) with the Nevada Secretary of State to designate 6,000 shares of its previously authorized preferred stock as Series C-2 Preferred Stock, par value $0.0001 per share and a stated value of $410.27 per share. The Series C-2 Certificate of Designation and its filing was approved by the Company’s board of directors without shareholder approval as provided for in the Company’s articles of incorporation and under Nevada law. The holders of shares of Series C-2 Preferred Stock have the following preferences and rights: ● Holders of shares of Series C-2 Preferred Stock are entitled to dividends or distributions on each share on an “as converted” into common stock basis, if, as and when declared from time to time by the Board of Directors. ● Each share of Series C-2 Preferred Stock is convertible into shares of common stock any time after the initial issuance date at a conversion price of $0.00275 per share. The number of shares of common stock issuable upon conversion shall be determined by dividing (x) (y) ● In the event the Company issues or sells any securities including options or convertible securities, except for any Exempt Issuance (as defined in the Series C-2 Certificate of Designation), at a price of or with an exercise price or conversion price of less than the conversion price, then upon such issuance or sale, the Series C-2 Preferred Stock conversion price shall be reduced to the sale price, the exercise price or conversion price of the securities sold. In addition, these preferred shareholders have the right to participate in future equity offerings from the company for twenty-four months from the effective date. ● In the event of the voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up of the Company, the holders of the Series C-2 Preferred Stock shall be entitled to receive, in cash out of the Liquidation Funds before any amount shall be paid to the holders of any shares of Junior Stock, but pari passu with any Parity Stock (as defined in the Series C-2 Certificate of Designation) then outstanding, an amount per shares of the Series C-2 Preferred Stock equal to the greater of (A) the conversion amount thereof on the date of such payment or (B) the amount per share such holder would receive if such holder converted such Series C-2 into common stock immediately prior to the date of the payment, provided that if the Liquidation Funds are insufficient to pay the full amount due to the holders of Series C-2 Preferred Stock and holders of the shares of Parity Stock, then each holder of Series C-2 Preferred Stock and each holder of Parity Stock shall receive a percentage of the Liquidation Funds equal to the full amount of the Liquidation Funds payable to such holder of Series C-2 Preferred Stock and such holder of the Parity Stock as a liquidation preference, in accordance with their respective certificate of designation (or equivalent), as a percentage of the full amount of Liquidation Funds payable to all holders of Series C-2 Preferred Stock and all holders of Parity Stock. On June 5, 2020, pursuant to the asset sale and recapitalization transaction (see Note 3), 4,916.865 shares of Series C-2 Preferred Stock was deemed to have been issued. As of September 30, 2020, the Company had 4,916.865 shares of Series C-2 Preferred Stock issued and outstanding. Series D-1 Preferred Stock On May 18, 2020, the Company filed a certificate of designation, preferences and rights of Series D-1 Preferred Stock (the “Series D-1 Certificate of Designation”) with the Nevada Secretary of State to designate 1,000 shares of its previously authorized preferred stock as Series D-1 Preferred Stock, par value $0.0001 per share and a stated value of $9,104.89 per share. The Series D-1 Certificate of Designation and its filing was approved by the Company’s board of directors without shareholder approval as provided for in the Company’s articles of incorporation and under Nevada law. The holders of shares of Series D-1 Preferred Stock had the following preferences and rights: ● Holders of shares of Series D-1 Preferred Stock were entitled to dividends or distributions on each share on an “as converted” into common stock basis, if, as and when declared from time to time by the Board of Directors. ● Each share of Series D-1 Preferred Stock is convertible into a pro rata portion of 54 . 55% of the Fully Diluted Equity (as defined in the Series D-1 Certificate of Designation) of the Company (the “Conversion Date”). ● Prior to the Conversion Date, each holder of Series D-1 Preferred Stock was entitled to the whole number of votes equal to the number of shares of common stock into which such holder’s Series D-1 vote or consent of stockholders, and otherwise had voting rights and powers equal to the voting rights and powers of the common stock. To the extent that under the Nevada Revised Statutes (“NRS”) the vote of the holders of the Series D-1, voting separately as a class or series as applicable, was required to authorize a given action, the affirmative vote or consent of the holders of a majority of the shares of the outstanding Series D-1, constituted the approval of such action by both the class or the series, as applicable (except as otherwise may be required under the NRS). During the year ended September 30, 2019, the Company issued 26 shares of D-1 Preferred Stock with grant date fair value of $100, for services. During the year ended September 30, 2019, the Company sold 5 shares of D-1 Preferred Stock for net proceeds of $1,599,469 of which $455,000 of the proceeds were from related parties (see Note 8). During the year ended September 30, 2020, the Company issued an aggregate of 1 share of D-1 Preferred Stock in exchange for the settlement of certain accrued compensation valued at $459,153 of which $160,000 was for a related party (see Note 8). During the year ended September 30, 2020, the Company sold 7 shares of D-1 Preferred Stock and warrants to purchase 656,674,588 shares of common stock, for net proceeds of $2,590,000. On September 24, 2020, the Company converted 1,000 shares of Series D-1 Preferred Stock into 5,081,550,620 shares of common stock (see below Common Stock As of September 30, 2020, there was no Series D-1 Preferred Stock issued and outstanding. Series D-2 Preferred Stock On May 18, 2020, the Company filed a certificate of designation, preferences and rights of Series D-2 Preferred Stock (the “Series D-2 Certificate of Designation”) with the Secretary of State of Nevada to designate 4,360 shares of its previously authorized preferred stock as Series D-2 Preferred Stock, par value $0.0001 per share and a stated value of $500 per share. The Series D-2 Certificate of Designation and its filing was approved by the Company’s board of directors without shareholder approval as provided for in the Company’s articles of incorporation and under Nevada law. The holders of shares of Series D-2 Preferred Stock have the following preferences and rights: ● Holders of shares of Series D-2 Preferred Stock are entitled to dividends or distributions on each share on an “as converted” into common stock basis, if, as and when declared from time to time by the Board of Directors. ● Each share of Series D-2 Preferred Stock are convertible into 10,000 shares of common stock (“Conversion Rate”). Upon the terms and in the manner set forth in Section 5 of the Series D-2 Certificate of Designation, each outstanding share of the Series D-2 Preferred Stock shall automatically be converted upon the effectiveness of the amendment to the Company’s Articles of Incorporation to increase the Company’s authorized common stock, par value $0.0001 per share, from 6,666,667 shares to 12,000,000,000 shares, which occurred on September 24, 2020 ( the “Conversion Date”). On this date the Series D-2 Preferred stock was converted into a number of fully-paid and nonassessable shares of Common Stock determined by multiplying such share of Series D-2 Preferred Stock by the Conversion Rate (such shares of Common Stock issuable upon Conversion, the “Conversion Shares”). ● Each holder of Series D-2 Preferred Stock shall be entitled to the whole number of votes equal to the number of shares of common stock the Series D-2 would be convertible into on the record date for the vote or consent of stockholders and shall otherwise have voting rights and powers equal to the voting rights and powers of common stock. To the extent that under the Nevada Revised Statues (“NRS”) the vote of the holders of the Series D-2 , voting separately as a class or series as applicable , is required to authorize a given action of the Corporation , the affirmative vote or consent of the holders of a majority of the shares of the outstanding Series D-2 , shall constitute the approval of such action by both the class or the series , as applicable (except as otherwise may be required under the NRS). ● In the event of the voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up of the Company, the holders of the Series D-2 Preferred Stock shall be entitled to receive, in cash out of the assets of the Company, whether from capital or from earnings available for distribution to its stockholders (“Liquidation Funds”) before any amount shall be paid to the holders of any shares of Junior Stock, but pari passu with any Parity Stock (as defined in the Certificate of Designation) then outstanding , an amount per shares of the Series D-2 Preferred Stock equal to the greater of (A) the Conversion Amount thereof on the date of such payment or (B) the amount per share such Holder would receive if such Holder converted such Series D-2 into common stock immediately prior to the date of the payment, provided that if the Liquidation Funds are insufficient to pay the full amount due to the Holders and holders of the shares of Parity Stock, then each Holder and each holder of Parity Stock shall receive a percentage of the Liquidation Funds equal to the full amount of the Liquidation Funds payable to such Holder and such holder of the Parity Stock as a liquidation preference, in accordance with their respective certificate of designation (or equivalent), as a percentage of the full amount of Liquidation Funds payable to all holders of Series D-2 Preferred Stock and all holders of Parity Stock. On June 5, 2020, the Company is deemed to have issued 4,121.64 shares of Series D-2 Preferred Stock pursuant to the Asset Sale Transaction and recapitalization. On September 24, 2020, the Company converted 4,121.64 shares of Series D-2 Preferred Stock into 41,216,000 shares of common stock (see below Common Stock As of September 30, 2020, there was no Series D-2 Preferred Stock issued and outstanding. Series E Preferred Stock On September 15, 2020, the Company filed a certificate of designation, preferences and rights of Series E Preferred Stock (the “Series E Certificate of Designation”) with the Nevada Secretary of the State to designate 2,000 shares of its previously authorized preferred stock as Series E Preferred Stock, par value $0.0001 per share and a stated value of $2,000 per share. The Series E Certificate of Designation and its filing was approved by the Company’s board of directors without shareholder approval as provided for in the Company’s articles of incorporation and under Nevada law (see Note 1). The holders of shares of Series E Preferred Stock have the following preferences and rights: ● From the initial issuance date, cumulative dividends on each share of Series E shall accrue, on a quarterly basis in arrears (with any partial quarter calculated on a pro-rata basis), at the rate of 8% per annum on the Stated Value, plus any additional amount thereon. Dividends shall be paid within 15 days after the end of each fiscal quarter (“Dividend Payment Date”), at the option of the Holder in cash or through the issuance of shares of common stock. In the event that the Holder elects to receive its dividends in shares of common stock the number of shares of common stock to be issued to each applicable Holder shall be determined by dividing the total dividend outstanding to such Holder by the average closing price of the common stock during the five trading days on the principal market prior to the Dividend Payment Date. ● Holders of shares of Series E Preferred Stock are entitled to dividends or distributions on each share on an “as converted” into common stock basis, if, as and when declared from time to time by the Board of Directors. ● Each share of Series E Preferred Stock is convertible into shares of common stock any time after the initial issuance date at the Conversion Price which is the lesser of: (i) $0.00375 or (ii) 75% of the average closing price of the common stock during the prior five trading days on the principal market, subject to adjustment as provided in the Series E Certificate of Designation including a price protection provision for offerings below the conversion price. Provided, however, the Conversion Price shall never be less than $0.0021. The number of shares of common stock issuable upon conversion shall be determined by multiplying the number of outstanding shares by the stated value per share of $2,000 plus accrued dividends and dividing that number by the Conversion Price. ● In connection with, (i) a Change of Control of the Corporation or (ii) on the closing of, a Qualified Public Offering by the Corporation, all of the outstanding shares of Series E (including any fraction of a share) shall automatically convert into an aggregate number of shares of Common Stock (including any fraction of a share) by multiplying the number of outstanding shares by the stated value per share of $2,000 plus accrued dividends and dividing that number (including any fraction of a share) by the lesser of: (i) $0.00375 or (ii) 75% of the average closing price of the common stock during the prior five trading days on the principle market. However, the conversion price shall never be less than $0.0021. If a closing of a Change of Control transaction or a Qualified Public Offering occurs, such automatic conversion of all of the outstanding shares of Series E shall be deemed to have been converted into shares of Common Stock immediately prior to the closing of such transaction or Qualified Public Offering. ● In the event the Company issues or sells any securities including options or convertible securities, except for any Exempt Issuance (as defined in the Series E Certificate of Designation), at a price, an exercise price or conversion price of less than the conversion price, then upon such issuance or sale, the Series E Preferred Stock conversion price shall be reduced to the sale price, the exercise price or the conversion price of the securities sold. ● Holders of Series E Preferred Stock have no voting rights. On September 16, 2020, the Company entered into a Securities Purchase Agreement (the “SPA”) with an investor to purchase an aggregate amount of 1,000 shares of the newly created Series E Convertible Preferred Stock of the Company (the “Series E Preferred”) for an aggregate investment amount of $2,000,000. The Company’s Series E Preferred Stock has a stated value of $2,000 per share and shall accrue, on a quarterly basis in arrears, dividends at the rate of 8% per annum on the stated value. The dividends shall be paid quarterly at the option of the holder of the Series E Preferred in either cash or shares of common stock of the Company. The Series E Preferred is convertible two days after the increase in the Company’s authorized common stock which became effective on September 24, 2020. The number of shares of common stock issuable on the conversion of the Series E Preferred is determined by dividing the stated value of the number of shares being converted, plus any accrued and unpaid dividends, by the lesser of: (i) $0.00375 and (ii) 75% of the average closing price of the Company’s common stock during the prior five trading days; provided, however, the conversion price shall never be less than $0.0021. For eighteen months from the anniversary of the closing, the Company needs to obtain consent from several investors prior to engaging in any future capital raises. Pursuant to the Series E Certificate of Designation, Series E Preferred Stock is redeemable at the option of the holder in the event that the Company is prohibited from issuing shares of common stock to a holder upon any conversion due to insufficient shares of common stock available (“Authorized Failure Shares”) and therefore meets the criteria of a contingently redeemable instrument in accordance with ASC 480-10-25-7 - Distinguishing Liabilities from Equity Further the Series E Preferred Stock is an equity host instrument since it has more features that align with an equity instrument than a debt instrument pursuant to ASC 815-15-25-17A - Derivatives and Hedging the nature of the host contract depends on the economic characteristics and risks of the entire hybrid financial instrument.” To determine whether the Series E Preferred Stock contains a beneficial conversion feature (“BCF”), we compared the effective conversion price and the Company’s stock price on the commitment date. The effective conversion price was calculated by dividing the proceeds from Series E Preferred Stock by the number of common shares issuable upon conversion of the Series E Preferred Stock. The BCF is measured as the difference between the commitment date stock price and the effective conversion price multiplied by the number of common stock issuable upon conversion of Series E. The BCF is limited to the total cash proceeds received if the amount of the BCF exceeds the cash proceeds received. In connection with the issuance of Series E Preferred Stock, during the year ended September 30, 2020, the Company recognized a beneficial conversion feature in the amount of $2,000,000 which was accounted for as a deemed dividend. In addition, during the year ended September 30, 2020, the Company also recorded dividends related to the Series E Preferred Stock in the amount of $6,120 which was reflected in the accompanying consolidated balance sheet in accrued liabilities. As of September 30, 2020, the Company had 1,000 shares of Series E Preferred Stock issued and outstanding classified as temporary equity in the accompanying consolidated balance sheet. Common Stock On June 5, 2020, the Company is deemed to have issued 1,398,070 shares of common stock pursuant to the Asset Sale Transaction and recapitalization. On September 24, 2020, the Company issued 5,081,550,620 shares of common stock upon the conversion of 1,000 shares of Series D-1 Preferred Stock (see above Series D-1 Preferred Stock On September 24, 2020, the Company issued 41,216,000 shares of common stock upon the conversion of 4,121.64 shares of Series D-2 Preferred Stock (see above Series D-2 Preferred Stock As of September 30, 2020, the Company had 5,124,164,690 shares of common stock outstanding of which 5,122,766,620 have not been issued yet. As of September 30, 2020, this common stock has not been issued yet as the Company is unable to issue shares of common stock until it is current with all its SEC reporting requirements. Stock Options Effective February 18, 2011, the Company’s Board of Directors (“Board”) adopted and approved the 2011 stock option plan. A total of 57 options to acquire shares of the Company’s common stock were authorized under the 2011 stock option plan. During each twelve-month period thereafter, our board of directors is authorized to increase the number of options authorized under this plan by up to 14 shares. No options were granted under the 2011 stock option plan as of September 30, 2020. On April 28, 2020, the Board approved the 2020 Equity Incentive Plan (the “Plan”), as amended on May 29, 2020. The Plan shall be effective upon approval by the Stockholders which shall be within twelve (12) months after the approval of the Board. No Incentive Stock Option shall be exercised unless and until the Plan has been approved by the Stockholders. Upon the effective date of the Plan and the effectiveness of the authorized share increase, which occurred on September 24, 2020, 3,043,638,781 shares of the Company’s common stock were being reserved for issuance under the Plan (the “Reserved Share Amount”), subject to the adjustments described in the Plan, and such Reserved Share Amount, when issued in accordance with the Plan, shall be validly issued, fully paid, and non-assessable. Pursuant to the Plan, the option price of each incentive stock option (except those that constitute substitute awards under the Plan) shall be at least the fair market value of a share of common stock on the respective grant date; provided, however, that in the event that a grantee is a ten-percent stockholder as of the grant date, the option price of an incentive stock option shall be not less than 110% of the fair market value of a share on the grant date. As of September 30, 2020, the 2020 Equity Incentive Plan has not yet been approved by the shareholders and certain grants are pending (see Note 10). As of September 30, 2020, the Company had no options issued and outstanding. Warrants In November 2019, in connection with the sale of 7 shares of Series D-1 Preferred Stock, the Company issued certain warrants to the subscriber. On June 5, 2020, in connection with the Asset Sale Transaction and recapitalization, the company issued 656,674,588 new warrants to the same subscriber in exchange for the previously issued warrants. The new warrants are exercisable immediately at an exercise price of $0.00214 and expire on November 27, 2024. On June 5, 2020, in connection with the Asset Sale Transaction and the recapitalization transaction, the Company is deemed to have issued 200,000,000 warrants to two investors. The warrants are not exercisable until sixty (60) days after the Company effectuates a reverse stock split and the Company achieves and maintains a Market Capitalization of $50,000,000 for thirty (30) consecutive days at an exercise price of $0.0025 and expire on September 5, 2025. As of September 30, 2020, the Company had 856,674,588 warrants issued and outstanding. Warrants activities for the year ended September 30, 2020 is summarized as follows: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Warrants Price Term (Years) Value Balance Outstanding at September 30, 2019 — $ — — $ — Warrants issued in connection with the sale of 7 shares of Series D-1 Preferred Stock 656,674,588 $ 0.002 4.2 $ — Deemed issuance in connection with the asset sale and recapitalization transaction (see Note 3) 200,000,000 $ 0.003 4.9 $ — Balance Outstanding at September 30, 2020 856,674,588 $ 0.002 4.3 $ — Exercisable at September 30, 2020 656,674,588 $ 0.002 4.2 $ —

Commitment and Contingencies

Commitment and Contingencies	12 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitment and Contingencies	NOTE 10 – COMMITMENT AND CONTINGENCIES Employment Agreements Michael Ruxin, M.D. On June 5, 2020, the Company and Dr. Michael Ruxin entered into an employment agreement (the “Ruxin Employment Agreement”) for Dr. Ruxin to serve as the Company’s Chief Executive Officer, President and a director (see Note 3). The Ruxin Employment Agreement provides that Dr. Ruxin will be employed for a five-year term commencing on June 5, 2020. The term will be automatically extended for one additional year upon the fifth anniversary of the effective date without any affirmative action, unless either party to the agreement provides at least sixty (60) days’ advance written notice to the other party that the employment period will not be extended. Dr. Ruxin will be entitled to receive an annual base salary of $300,000 and will be eligible for an annual discretionary bonus of 150% of such base salary. In the Ruxin Employment Agreement, Dr. Ruxin is also promised, subject to the approval of the Board or a committee thereof, and under the 2020 Equity Incentive Plan (i) a one-time grant of 49,047,059 Restricted Stock Units (“RSUs”) and (ii) a one-time grant of options to purchase 420,691,653 shares of Common Stock, both of which will be subject to the terms and conditions of the applicable award agreements when executed. Dr. Ruxin is entitled to participate in any and all benefit plans, from time to time, in effect for senior management, along with vacation, sick and holiday pay in accordance with the Company’s policies established and in effect from time to time. As of September 30, 2020, the RSUs and options have not yet been granted or issued since the Board has not yet approved the grants and the 2020 Equity Incentive Plan has not been approved by the shareholders. Further, the board and Dr. Ruxin have not yet agreed on the terms of the options. Dr. Ruxin is an “at-will” employee and his employment may be terminated by the Company at any time, with or without cause. In the event Dr. Ruxin’s employment is terminated by the Company without Cause (as defined in the Ruxin Agreement), with Good Reason (as defined in the Ruxin Agreement) or as a result of a non-renewal of the term of employment under the Ruxin Agreement, Dr. Ruxin shall be entitled to receive the sum of (I) the Severance Multiple (as defined below), multiplied by multiplied by provided, however The Ruxin Agreement also contains covenants (a) restricting the executive from engaging in any activity competitive with our business during the term of the employment agreement and in the event of termination, for a period of one year thereafter, (b) prohibiting the executive from disclosing confidential information regarding the Company, and (c) soliciting employees, customers and prospective customers during the term of the employment agreement and for a period of one year thereafter. Jeffrey Busch On June 5, 2020, the Company and Jeffrey Busch entered into an employment agreement (the “Busch Employment Agreement”) for Mr. Busch to serve as the Company’s Chairman of the Board of Directors (see Note 3). The Busch Employment Agreement provides that Mr. Busch will be employed for a five-year term commencing on June 5, 2020. The term will be automatically extended for one additional year upon the fifth anniversary of the effective date without any affirmative action, unless either party to the agreement provides at least sixty (60) days’ advance written notice to the other party that the employment period will not be extended. Mr. Busch will be entitled to receive an annual base salary of $60,000 and will be eligible for an annual discretionary bonus. In the Busch Employment Agreement, Mr. Busch is also promised, subject to the approval of the Board or committee thereof, and under the 2020 Equity Incentive Plan (i) a one-time grant of 49,047,059 Restricted Stock (“RSUs”) and (ii) a one-time grant of options to purchase 420,691,653 shares of Common Stock, both of which will be subject to the terms and conditions of the applicable award agreements when executed. Mr. Busch is entitled to participate in any and all benefit plans, from time to time, in effect for senior management, along with vacation, sick and holiday pay in accordance with the Company’s policies established and in effect from time to time. As of September 30, 2020, the RSUs and options have not yet been granted or issued since the Board has not yet approved the grants and the 2020 Equity Incentive Plan has not been approved by the shareholders. Further, the board and Mr. Busch have not yet agreed on the terms of the options. As of September 30, 2020 and 2019, the Company had accrued director compensation of $72,500 and $70,000, respectively. Mr. Busch is an “at-will” employee and his employment may be terminated by the Company at any time, with or without cause. In the event Mr. Busch’s employment is terminated by the Company without Cause (as defined in the Busch Agreement), with Good Reason (as defined in the Busch Agreement) or as a result of a non-renewal of the term of employment under the Busch Agreement, Mr. Busch shall be entitled to receive the sum of (I) the Severance Multiple (as defined below), multiplied by multiplied by provided, however The Busch Agreement also contains covenants (a) restricting the executive from engaging in any activity competitive with our business during the term of the employment agreement and in the event of termination, for a period of one year thereafter, (b) prohibiting the executive from disclosing confidential information regarding the Company, and (c) soliciting employees, customers and prospective customers during the term of the employment agreement and for a period of one year thereafter. Thomas E. Chilcott, III On September 24, 2020, the Company appointed Thomas E. Chilcott, III, to serve as the Chief Financial Officer. The Company entered into an offer letter with Mr. Chilcott which provides that his base salary will be $225,000 per year and that he will be eligible to receive the following bonuses: $5,000 if the Company’s next Annual Report on Form 10-K is filed on or prior to December 12, 2020; $5,000 if the Company files a registration statement on Form S-1 on or prior to January 15, 2021; $5,000 if the Company completes a capital raise of at least $3,000,000 on or prior to Apri1 15, 2021; $20,000 if the Company completes a capital raise of at least $10,000,000 on or prior to September 30, 2021; and $15,000 if the Company successfully lists on the Nasdaq stock market on or before December 31, 2021. Mr. Chilcott is entitled to participate in all medical and other benefits that the Company has established for its employees. The offer letter also provides that Mr. Chilcott will be granted an option to purchase up to 94,545,096 shares of the Company’s common stock subject to terms including exercise price to be set by the Board of Directors of the Company (see Note 1). As of September 30, 2020, no bonus was due and no options have been granted to Mr. Chilcott. Consulting Agreements On July 5, 2020, the Company and a consultant entered into a Scientific Advisory Board Service Agreement (the “Advisory Agreement”) which provides for; (i) $2,000 monthly compensation; (ii) 88,786,943 stock options under the 2020 Equity Incentive Plan and; (iii) $1,500 per day for any special project requiring more than six hours of advisory service in a single day, performed upon a written request from the Company. Either party may terminate the Advisory Agreement at any time upon ten days written notice to the other party unless either party neglects or fails to perform its obligations under the Advisory Agreement then the termination notice shall be effective upon receipt of the same. As of September 30, 2020, the Company and the consultants have not agreed on the terms of the 88,786,943 stock options and therefore these stock options are not considered granted by the Company. Further, as of September 30, 2020, the 2020 Equity Incentive Plan has not yet been approved by the shareholders. On July 5, 2020, the Company and a consultant entered into a Pathology Advisory Board Service Agreement (the “Advisory Agreement”) which provides for; (i) $272 monthly compensation; (ii) 77,972,192 stock options under the 2020 Equity Incentive Plan and; (iii) $1,500 per day for any special project requiring more than six hours of advisory service in a single day, performed upon a written request from the Company. Either party may terminate the Advisory Agreement at any time upon ten days written notice to the other party unless either party neglects or fails to perform its obligations under the Advisory Agreement then the termination notice shall be effective upon receipt of the same. As of September 30, 2020, the Company and the consultants have not agreed on the terms of the 77,972,192 stock options and therefore these stock options are not considered granted by the Company. Further, as of September 30, 2020, the 2020 Equity Incentive Plan has not yet been approved by the shareholders. License Agreements GMU License Agreement In September 2006, the Company entered into an exclusive license agreement (“License Agreement”) with George Mason Intellectual Properties, a non-profit corporation formed for the benefit of GMU which: (1) grants an exclusive worldwide license, with the right to grant sublicenses, under the licensed inventions to make, have made, import, use, market, offer for sale and sell products designed, manufactured, used and/or marketed for all fields and for all uses, subject to the exclusions as defined in the License Agreement; (2) grants an exclusive option to license past, existing, or future inventions in the Company’s field, from inventors that are obligated to assign to GMU and who have signed a memorandum of understanding acknowledging that developed intellectual property will be offered, subject to the exclusions as defined in the License Agreement; (3) the license and option granted specifically excludes biomarkers for lung, ovarian, and breast cancers in a diagnostic field of use and GMU inventions developed using materials obtained from third parties under agreements granting rights to inventions made using said materials and; (4) grants right to assign or otherwise transfer the license so long as such assignment or transfer is accompanied by a change of control transaction and GMU is given 14 days prior notice. In addition, the Company is required to make an annual payment of $50,000 to GMU as well as pay GMU a quarterly royalty equal to the net revenue multiplied by one and one-half percent (1.5%), due on a quarterly basis or a quarterly sublicense royalty equal to the net revenue multiplied by fifteen percent (15%). Further, the Company has the right of first refusal for all technology associated with RPPA technology from GMU. As of September 30, 2020, the Company has accrued royalty fees and accrued license fees of $832 and $2,083, respectively, reflected in the accompanying consolidated balance sheet in accrued liabilities. NIH License Agreement In March 2018, the Company entered into two license agreements (“License Agreements”) with the National Institutes of Health (“NIH”) which grants the Company an exclusive and a nonexclusive United States license for certain patents. Pursuant to the License Agreements, the Company is required to make an annual payment of $6,000 to the NIH as well as pay the NIH a royalty equal to the net sales multiplied by three percent (3.0%) every June 30 th st st Employee Incentive Stock Options In June 2020, in connection with the asset sale transaction (see Note 3), the Company planned to issue approximately 1.8 billion stock options to employees, which include options in the employment agreements discussed above. As of September 30, 2020, these stock options had not yet been granted by the Company. Lease In December 2019, the Company entered into an agreement to lease its corporate and laboratory facility in Golden, Colorado. The lease is for a period of 60 months, with an option to extend, commencing in February 2020 and expiring in February 2025 (see Note 7). Other Contingencies Pursuant to ASC 450-20 - Loss Contingencies, liabilities for contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. As of September 30, 2020, the Company recorded a contingent liability of $64,040, resulting from certain liabilities of Avant prior to the asset sale and recapitalization transaction (see Note 3 and Note 6). The contingent liabilities consisted of two notes payables with a total outstanding principal balance of $40,000 and accrued interest payable of $24,040 for a total amount of $64,040 as of September 30, 2020.

Income Taxes

Income Taxes	12 Months Ended
	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 11 – INCOME TAXES The Company maintains deferred tax assets and liabilities that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The deferred tax assets on September 30, 2020 and 2019 consist of net operating loss carry-forwards. The net deferred tax asset has been fully offset by a valuation allowance because of the uncertainty of the attainment of future taxable income. The items accounting for the difference between income taxes at the effective statutory rate and the provision for income taxes for the fiscal years ended September 30, 2020 and 2019 are as follow: Years Ended September 30, 2020 2019 Income tax benefit at U.S. statutory rate of 21%  $ (665,756 ) $ (335,595 ) Income tax benefit – state (146,783 ) (73,980 ) Non-deductible expenses (53,244 ) 10,483 Change in valuation allowance 865,783 399,402 Total provision for income tax $ — $ — The Company’s approximate net deferred tax asset as of September 30, 2020 and 2019 was as follow: Years Ended September 30, 2020 2019 Net operating loss carry-forwards $ 9,790,195 $ 8,924,412 Total deferred tax asset 9,790,195 8,924,412 Less: valuation allowance (9,790,195 ) (8,924,412 ) Net deferred tax asset $ — $ — The gross operating loss carry forward available to the Company was $38,198,187 at September 30, 2020. The Company provided a full valuation allowance equal to the net deferred income tax asset as of September 30, 2020 and 2019 because it was not known whether future taxable income will be sufficient to utilize the loss carry-forwards. Additionally, the future utilization of the net operating loss carry-forwards to offset future taxable income is subject to annual limitations as a result of ownership or business changes that occurred prior to fiscal year 2020 and may occur in the future. The Company has not conducted a study to determine the limitations on the utilization of these net operating loss carry-forwards. The increase in the valuation allowance was $865,783 in fiscal year 2020 and total net loss carry-forwards on September 30, 2020 was $9,790,195. The potential tax benefit arising from the loss carry-forward of approximately $8,050,201 accumulated through September 30, 2017, will expire in 2037. The potential tax benefit arising from the net operating loss carry-forward of $1,739,994 occurred after the effective date of the current tax act and can be carried forward indefinitely within the annual usage limitations.

Subsequent Events

Subsequent Events	12 Months Ended
	Sep. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE 12 – SUBSEQUENT EVENTS Sale of Common Stock From February 16, 2021 through April 14, 2021, the Company, entered into Subscription Agreements with fourteen accredited investors to sell, in a private placement, an aggregate of 431,309,904 shares of its common stock, par value $0.0001 per share, at a purchase price of $0.00313 per share for an aggregate purchase price of $1,350,000. The Shares sold by the Company under these Subscription Agreements were in reliance upon an exemption from the registration requirements of the Act afforded by Section 4(a)(2) of the Act and/or Rule 506 of Regulation D thereunder. The private placements were made directly by the Company and no underwriter or placement agent was engaged by the Company. The Company did not engage in general solicitation or advertising and did not offer securities to the public in connection with this offering. Note Agreements On April 26, 2021, the Company entered into a Promissory Note Agreement (the “Note”) with Jeffrey Busch who serves as a member of the Board of Directors (“Lender”) for a principal amount of $100,000. The Company received proceeds of $100,000. The Note bears an annual interest rate of 1%, matures on April 1, 2022 and can be prepaid in whole or in part without penalty. Pursuant to the Note, the Company has a 90-day grace period following the maturity date after which the Lender shall charge a late payment fee equal to 1% of the outstanding principal balance and cost of collection, including legal fees. On May 12, 2021, the Company entered into a Securities Purchase Agreement (the “SPA”) with an affiliated investor (the “Investor”) to purchase a convertible note (the “Note”) and accompanying warrant (the “Warrant”) for an aggregate investment amount of $1,000,000. The Note has a principal value of $1,000,000 and bears an interest rate of 8% per annum (which shall increase to 10% per year upon the occurrence of an “Event of Default” (as defined in the Note)) and shall mature on May 12, 2026 (the “Maturity Date”). The Company received the proceeds in three tranches with the first tranche of $333,334 received in May 2021, the second tranche of $333,333 received in June 2021 and the third tranche of $333,333 received in July 2021. The Note is convertible at any time into shares of the Company’s common stock at a conversion price equal to $0.00313 per share for any amount of principal and accrued interest remaining outstanding (subject to adjustment as provided therein). The Note had a beneficial conversion feature in the amount of $15,800 which was recorded as debt discount to be amortized over the life of the Note. The Company may prepay the Note at any time in an amount equal to 110% of the outstanding principal balance and accrued interest. In connection with the Note, the Investor was issued a Warrant to purchase up to 63,897,764 shares of common stock at an exercise price of $0.00313 per share (subject to adjustment as provided therein) until May 12, 2026. The Warrants are exercisable for cash at any time. The 63,897,764 stock warrant was valued at $984,200 using the relative fair value method which was recorded as debt discount to be amortized over the life of the Note. In connection with the Company’s obligations under the Note, the Company entered into a security agreement (the “Security Agreement”) with Ashton Capital Corporation as agent, pursuant to which the Company granted a lien on certain pieces of laboratory equipment of the Company (the “Collateral”), for the benefit of the Investor, to secure the Company’s obligations under the Note. Upon an Event of Default (as defined in the Notes), the Investor may, among other things, collect or take possession of the Collateral, proceed with the foreclosure of the security interest in the Collateral or sell, lease or dispose of the Collateral. Amendment to Lease On June 10, 2021, the Company entered into an amendment to its existing Warehouse Lease (the “Lease Amendment”) for its laboratory facility in Golden, CO. The amendment was entered into in order to: (i) extend the term of the lease to five years following completion of the Company’s improvements to the Expansion Premises (defined below);(ii) expand the premises to include the premises located at Unit 404, Building F, 15000 West 6th Avenue, Golden, Colorado 80401, consisting of approximately 4,734 rentable square feet (the “Expansion Premises”); (iii) modify the annual basic rent; (iv) increase the security deposit; (v) provide for a tenant improvement allowance; (vi) provide for additional parking; (vii) provide for renewal options; and (viii) make certain other modifications as more particularly set forth below. Pursuant to the Lease Amendment, the Company must pay a monthly base rent of; (i) $5,660 for the year from 3/1/25 to 2/28/26 and (ii) $5,829 for each year thereafter. In addition, the Company must pay a monthly base rent for the Expanded Premises of; (i) $4,537 in the first year; (ii) $4,673 in the second year; (iii) $4,813 in the third year; (iv) $4,957 in the fourth year and; (v) $5,106 in the fifth year. Certificate of Designation of Series F Preferred Stock On June 30, 2021, the Company filed a certificate of designation, preferences and rights of Series F Preferred Stock (the “Series F Certificate of Designation”), with the Nevada Secretary of State to designate 1,000 shares of its previously authorized preferred stock as Series F Preferred Stock, par value $0.0001 per share and a stated value of $2,000 per share. The Series F Certificate of Designation and its filing was approved by the Company’s board of directors without shareholder approval as provided for in the Company’s articles of incorporation and under Nevada law (see Note 1). The holders of shares of Series F Preferred Stock have the following preferences and rights: ● From the Initial Issuance Date, cumulative dividends on each share of Series F shall accrue, on a monthly basis in arrears (with any partial month being made on a pro-rata basis), at the rate of 8% per annum on the Stated Value, plus the Additional Amount thereon. Dividends shall be paid within 15 days after the end of each month (“Dividend Payment Date”), at the option of the Holder in cash or through the issuance of shares of Common Stock. In the event that the Holder elects to receive its dividends in shares of Common Stock the number of shares of Common Stock to be issued to each applicable Holder shall be calculated by dividing the total dividend due to such Holder by the average closing price of the Common Stock during the five trading days on the Principal Market prior to the Dividend Payment Date. ● Holders of shares of Series F Preferred Stock are entitled to dividends or distributions on each share on an “as converted” into common stock basis, if, as and when declared from time to time by the Board of Directors. ● Each share of Series F Preferred Stock is convertible into shares of common stock any time after the initial issuance date at the Conversion Price which is the lesser of: (i) $0.00313 or (ii) 75% of the average closing price of the common stock during the prior five trading days on the principal market, subject to adjustment as provided in the Series F Certificate of Designation including a price protection provision for offerings below the conversion price. Provided, however, the Conversion Price shall never be less than $0.0016. The number of shares of common stock issuable upon conversion shall be determined by multiplying the number of outstanding shares by the stated value per share of $2,000 plus any additional amount and dividing the total by the Conversion Price. ● In connection with, (i) a Change of Control of the Corporation or (ii) on the closing of, a Qualified Public Offering by the Corporation, all of the outstanding shares of Series F Preferred Stock (including any fraction of a share) shall automatically convert along with any additional amount into an aggregate number of shares of Common Stock (including any fraction of a share) as is determined by dividing the number of shares of Series F Preferred Stock (including any fraction of a share) by the Automatic Conversion Price then in effect. If a closing of a Change of Control transaction or a Qualified Public Offering occurs, such automatic conversion of all of the outstanding shares of Series F Preferred Stock shall be deemed to have been converted into shares of Common Stock immediately prior to the closing of such transaction or Qualified Public Offering. ● In the event the Company issues or sells any securities including options or convertible securities, except for any Exempt Issuance (as defined in the Series F Certificate of Designation), at a price, an exercise price or conversion price of less than the conversion price, then upon such issuance or sale, the Series F Preferred Stock conversion price shall be reduced to the sale price, or the exercise price or conversion price of the securities sold. ● Series F Preferred Stock shall rank pari passu with respect to preferences to dividends, distributions and payments upon the liquidation, dissolution and winding up of the Corporation with the Series C-1 Preferred Stock of the Corporation, the Series C-2 Preferred Stock of the Corporation, and the Series E Preferred Stock of the Corporation (the “Parity Stock”), and all other shares of capital stock of the Corporation shall be junior in rank to all Series F with respect to the preferences as to dividends (except for the Common Stock, which shall be pari passu as provided in the Series F Certificate of Designation), distributions and payments upon the liquidation, dissolution and winding up of the Corporation (such junior stock is referred to herein collectively as “Junior Stock”). The rights of all such Junior Stock shall be subject to the rights, powers, preferences and privileges of the Series F Preferred Stock. Without limiting any other provision of the Series F Certificate of Designation, without the prior express consent of the Required Holder, the Corporation shall not hereafter authorize or issue any additional or other shares of capital stock that is (i) of senior rank to the Series F Preferred Stock in respect of the preferences as to dividends, distributions and payments upon the liquidation, dissolution and winding up of the Corporation (collectively, the “Senior Preferred Stock”), or (ii) Parity Stock. Except as provided for herein, in the event of the merger or consolidation of the Corporation into another corporation, the Series F Preferred Stock shall maintain its relative rights, powers, designations, privileges and preferences provided for herein for a period of at least two years following such merger or consolidation and no such merger or consolidation shall cause result inconsistent therewith. Legal Action On July 1, 2021, numerous purported plaintiffs brought an action against Avant and their previous executive team in the District Court of Harris County Texas. The action alleges the plaintiffs were engaged by Avant to perform services prior to 2018. The plaintiffs are seeking a $1 million award. The Company and Dr. Ruxin were named it the lawsuit. The Company believes these claims are without merit and intends to defend these lawsuits vigorously. The Company currently believes the likelihood of a loss contingency related to these matters is remote and, therefore, no provision for a loss contingency is required. Sale of Series F Preferred Stock On July 30, 2021, the Company entered into a Securities Purchase Agreement (the “SPA”) with an investor to purchase an aggregate amount of 500 shares of a newly created Series F Convertible Preferred Stock of the Company (the “Series F Preferred”) and accompanying warrant (the “Warrant”) for an aggregate investment amount of $1,000,000. The Series F Preferred Stock has a stated value of $2,000 per share and shall accrue monthly in arrears, dividends at the rate of 8% per annum on the stated value. The dividends shall be paid monthly at the option of the holder of the Series F Preferred in either cash or shares of common stock of the Company. The number of shares of common stock issuable upon conversion of the Series F Preferred is determined by dividing the stated value of the number of shares being converted, plus any accrued and unpaid dividends, by the lesser of: (i) $0.00313 and (ii) 75% of the average closing price of the Company’s common stock during the prior five trading days; provided, however, the conversion price shall never be less than $0.0016. In addition, the investor was issued a Warrant to purchase an amount of common stock equal to 20% of the shares of common stock issuable upon conversion of the Series F Preferred at an exercise price of $0.00313 per share (subject to adjustment as provided therein) until July 30, 2026. The Warrants are exercisable for cash at any time. The Warrants shall be valued using the relative fair value method. Series E Price Reduction The Series F Preferred Stock, that was issued on July 30, 2021, triggered the price protection clause in the Series E Preferred Stock. Thus, the conversion price of the Series E Preferred Stock was reduced from $0.00375 to $0.00313 on that date. Exercise of Options to Purchase Shares of OncBioMune Sub Inc. In connection with the Asset Sale Transaction, the Company entered into an Exchange Agreement, effective June 5, 2020, by and among OncBioMune Pharmaceuticals, Inc. and the investors named therein, whereby the Company agreed to exchange certain convertible promissory notes and warrants outstanding for shares of Series C-1 Convertible Preferred Stock of the Company and options to purchase shares of the Company’s wholly-owned subsidiary, OncBioMune Sub Inc. OncBioMune Sub Inc. holds the patents use in the prior business of OncBioMune Pharmaceuticals, Inc. In July of 2021, certain of those investors exercised their options to purchase the shares of OncBioMune Sub Inc. On July 26, 2021, the Company transferred all 10,000 shares of OncBioMune Sub Inc. held by the Company to the investors.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America which present the consolidated financial statements of the Company and its wholly-owned inactive subsidiaries, OncBioMune, Inc. and OncBioMune Sub, Inc., as of September 30, 2020. Since there was no subsidiary, the financial statements are not consolidated as of September 30, 2019. All intercompany accounts and transactions have been eliminated in consolidation.
Going Concern	Going Concern These consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying consolidated financial statements, the Company had net loss and net cash used in operations of $3,170,267 and $3,470,755, respectively, for the year ended September 30, 2020. Additionally, the Company had an accumulated deficit, stockholders’ deficit and working capital of $43,187,588, $307,595 and $877,234 at September 30, 2020. Management believes that these matters raise substantial doubt about the Company’s ability to continue as a going concern for twelve months from the issuance date of this report. The Company cannot provide assurance that it will ultimately achieve profitable operations or become cash flow positive or raise additional debt or equity capital. Additionally, the current capital resources are not adequate to continue operating and maintaining the business strategy for a period of twelve months from the issuance date of this report. The Company will seek to raise capital through additional debt and equity financings to fund its operations in the future. Although the Company has historically raised capital from sales of equity and from the issuance of promissory notes, there is no assurance that it will be able to continue to do so. If the Company is unable to raise additional capital or secure additional lending in the near future, management expects that the Company will need to curtail or cease operations. These consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The global pandemic COVID-19, otherwise referred to as the Coronavirus, could impair our ability to raise additional funding or make such funding more costly. The ongoing global pandemic has caused cessation of normal business operations and initially caused capital markets to decline sharply. This could make it more difficult for the Companies to access capital. It is currently difficult to estimate with any certainty how long the pandemic and resulting curtailment of business will continue, and its effect on capital markets and the Company’s ability to raise funds is, accordingly, difficult to quantify. In addition, to the extent that any of the Company’s personnel or consultants are affected by the virus, this could cause delays or disruption in our planned research and development activities.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make judgments, assumptions, and estimates that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Management bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. Significant estimates during the years ended September 30, 2020 and 2019 include, but are not necessarily limited to, the valuation of assets and liabilities of discontinued operations, estimates of contingent liabilities, valuation of marketable securities, useful life of property and equipment, valuation of right-of-use (“ROU”) assets and lease liabilities, assumptions used in assessing impairment of long-lived assets, allowances for accounts receivable, estimates of current and deferred income taxes and deferred tax valuation allowances and the fair value of non-cash equity transactions. Additionally, the full impact of COVID-19 is unknown and cannot be reasonably estimated. However, the Company has made appropriate accounting estimates based on the facts and circumstances available as of the reporting date. To the extent there are material differences between the Company’s estimates and the actual results, the Company’s future consolidated results of operation will be affected.
Fair Value of Financial Instruments and Fair Value Measurements	Fair Value of Financial Instruments and Fair Value Measurements FASB ASC 820 - Fair Value Measurements and Disclosures, defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. FASB ASC 820 requires disclosures about the fair value of all financial instruments, whether or not recognized, for financial statement purposes. Disclosures about the fair value of financial instruments are based on pertinent information available to the Company on September 30, 2020. Accordingly, the estimates presented in these financial statements are not necessarily indicative of the amounts that could be realized on disposition of the financial instruments. FASB ASC 820 specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The three levels of the fair value hierarchy are as follows: Level 1—Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. Level 2—Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. Level 3—Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. In August 2018, the FASB issued ASU 2018-13 —Fair Value Measurement (Topic 820): Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. The Company’s investment policy is to preserve principal and maintain liquidity. The Company periodically monitors its positions with, and the credit quality of, the financial institutions with which it invests. The Company maintains its cash in banks and financial institutions that at times may exceed federally insured limits. There were cash balances in excess of FDIC insured levels of $1,538,951 and $310,407 as of September 30, 2020 and 2019, respectively. The Company has not experienced any losses in such accounts through September 30, 2020.
Prepaid Assets	Prepaid Assets Prepaid assets are carried at amortized cost. Significant prepaid assets as of September 30, 2020 and 2019 include, but are not necessarily limited to, prepaid insurance, prepaid consulting fees, prepaid equipment maintenance fee and retainers for professional services.
Laboratory Supplies	Laboratory Supplies Laboratory supplies are normally consumed within a year from purchase and any unused laboratory supplies are classified as current asset and reflected in the accompanying consolidated balance sheet as laboratory supplies.
Property and Equipment	Property and Equipment Fixed assets are stated at cost and depreciated using the straight-line method over their estimated useful lives, which range from three to five years. Leasehold improvements are depreciated over the shorter of the useful life or lease term including scheduled renewal terms. Maintenance and repairs are charged to expense as incurred. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the year of disposition. The Company examines the possibility of decreases in the value of these assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable.
Impairment of Long-lived Assets	Impairment of Long-Lived Assets In accordance with ASC Topic 360, the Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable, or at least annually. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value.
Stock-based Compensation	Stock-Based Compensation Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. Pursuant to ASC 505-50 - Equity-Based Payments to Non-Employees, all share-based payments to non-employees, including grants of stock options, were recognized in the consolidated financial statements as compensation expense over the service period of the consulting arrangement or until performance conditions are expected to be met. Using a Black Scholes valuation model, the Company periodically reassessed the fair value of non-employee options until service conditions are met, which generally aligns with the vesting period of the options, and the Company adjusts the expense recognized in the consolidated financial statements accordingly. In June 2018, the FASB issued ASU No. 2018-07, Improvements to Nonemployee Share-Based Payment Accounting, which simplifies several aspects of the accounting for nonemployee share-based payment transactions by expanding the scope of the stock-based compensation guidance in ASC 718 to include share-based payment transactions for acquiring goods and services from non-employees. ASU No. 2018-07 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods. Early adoption is permitted, but entities may not adopt prior to adopting the new revenue recognition guidance in ASC 606. The Company early adopted ASU No. 2018-07 during the period September 30, 2018, and the adoption did not have any impact on its consolidated financial statements.
Revenue Recognition	Revenue Recognition In May 2014, FASB issued an Accounting Standards Update, ASU 2014-09, establishing ASC 606 - Revenue from Contracts with Customers. ASU 2014-09, as amended by subsequent ASUs on the topic, establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard, which is effective for interim and annual reporting periods in fiscal years that begin after December 15, 2017, requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures. The Company adopted this standard during the fiscal year ended September 30, 2018 using the modified retrospective approach, which requires applying the new standard to all existing contracts not yet completed as of the effective date and recording a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. Based on an evaluation of the impact ASU 2014-09 will have on the Company’s sources of revenue, the Company has concluded that ASU 2014-09 did not have any impact on the process for, timing of, and presentation and disclosure of revenue recognition from customers and there was no cumulative effect adjustment. The Company provides research and development support to biopharmaceutical companies to assist their drug development programs. The services provided by the Company are performance obligations under services contracts. These contracts are completed over time and may lead to deferred revenue for services not completed at the end of a period. Management reviews the completion status of all jobs monthly to determine the appropriate amount of revenue to recognize.
Cost of Revenue	Cost of Revenue The cost of revenue consists of cost of labor, supplies and materials.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis and do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired.
Concentrations	Concentrations Concentration of Revenues During the year ended September 30, 2020, the Company generated total revenue of $181,229 of which 56% and 44% were from two of the Company’s customers. During the year ended September 30, 2019, the Company did not have any revenue.
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share Pursuant to ASC 260-10-45, basic loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the periods presented. Diluted loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. Potentially dilutive common shares consist of common stock issuable for stock options and warrants (using the treasury stock method), convertible notes and common stock issuable. These common stock equivalents may be dilutive in the future. The following potentially dilutive equity securities outstanding as of September 30, 2020 and 2019 were not included in the computation of dilutive loss per common share because the effect would have been anti-dilutive: September 30, 2020 2019 Stock warrants 856,674,588 — Series C-1 preferred stock 445,301,289 — Series C-2 preferred stock 733,542,619 — Series D-1 preferred stock — 4,392,557,509 Series E preferred stock 533,333,333 — 2,568,851,829 4,392,557,509
Income Taxes	Income Taxes The Company accounts for income tax using the liability method prescribed by ASC 740 - Income Taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company follows the accounting guidance for uncertainty in income taxes using the provisions of ASC 740 “Income Taxes
Related Parties	Related Parties Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal with if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.
Leases	Leases In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, Leases On January 1, 2019, the Company adopted ASU No. 2016-02, applying the package of practical expedients to leases that commenced before the effective date whereby the Company elected to not reassess the following: (i) whether any expired or existing contracts contain leases and; (ii) initial direct costs for any existing leases. For contracts entered into on or after the effective date, at the inception of a contract the Company assessed whether the contract is, or contains, a lease. The Company’s assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether the Company has the right to direct the use of the asset. The Company will allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments. The Company has elected not to recognize right-of-use (“ROU”) assets and lease liabilities for short-term leases that have a term of 12 months or less. Operating and financing lease ROU assets represents the right to use the leased asset for the lease term. Operating and financing lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. As most leases do not provide an implicit rate, the Company use an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general and administrative expenses in the consolidated statements of operations.
Reclassifications	Reclassifications On the consolidated balance sheet as of September 30, 2019, (i) $4,000 of accounts receivable has been reclassified to other receivables and (ii) $70,000 of accrued liabilities has been reclassified to accrued director compensation, to conform to the September 30, 2020 consolidated balance sheet presentation. These reclassifications do not have a significant impact on the reported financial position and does not impact the results of operations or cash flows.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06— Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and edging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”) Debt with Conversion and Other Options 1. Add a disclosure objective 2. Add information about events or conditions that occur during the reporting period that cause conversion contingencies to be met or conversion terms to be significantly changed 3. Add information on which party controls the conversion rights 4. Align disclosure requirements for contingently convertible instruments with disclosure requirements for other convertible instruments 5. Require that existing fair value disclosures in Topic 825, Financial Instruments, be provided at the individual convertible instrument level rather than in the aggregate. Additionally, for convertible debt instruments with substantial premiums accounted for as paid-in capital, amendments in ASU 2020-06 added disclosures about (1) the fair value amount and the level of fair value hierarchy of the entire instrument for public business entities and (2) the premium amount recorded as paid-in capital. The amendments in ASU 2020-06 are effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Entities should adopt the guidance as of the beginning of its annual fiscal year and is allowed to adopt the guidance through either a modified retrospective method of transition or a fully retrospective method of transition. In applying the modified retrospective method, entities should apply the guidance to transactions outstanding as of the beginning of the fiscal year in which the amendments are adopted. Transactions that were settled (or expired) during prior reporting periods are unaffected. The cumulative effect of the change should be recognized as an adjustment to the opening balance of retained earnings at the date of adoption. If an entity elects the fully retrospective method of transition, the cumulative effect of the change should be recognized as an adjustment to the opening balance of retained earnings in the first comparative period presented. The Company is evaluating the impact of the revised guidance and believes that it will not have a significant impact on its consolidated financial statements. Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the Company’s consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Schedule of Anti-dilutive Shares Outstanding	The following potentially dilutive equity securities outstanding as of September 30, 2020 and 2019 were not included in the computation of dilutive loss per common share because the effect would have been anti-dilutive: September 30, 2020 2019 Stock warrants 856,674,588 — Series C-1 preferred stock 445,301,289 — Series C-2 preferred stock 733,542,619 — Series D-1 preferred stock — 4,392,557,509 Series E preferred stock 533,333,333 — 2,568,851,829 4,392,557,509

Asset Sale and Recapitalizati_2

Asset Sale and Recapitalization Transaction (Tables)	12 Months Ended
	Sep. 30, 2020
Business Combination and Asset Acquisition [Abstract]
Schedule of Assets and Liabilities in Transaction	The following assets and liabilities were assumed in the transaction: Cash $ 675,928 Prepaid expense and other current assets 17,539 Total assets acquired 693,467 Accounts payable and other liabilities (40,149 ) Liabilities of discontinued operations (406,662 ) Total liabilities assumed (446,811 ) Net assets acquired $ 246,656

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Sep. 30, 2020
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Fixed assets consist of the following: Estimated Useful Life in Years September 30, 2020 September 30, 2019 Laboratory equipment 5 $ 404,628 $ 103,247 Furniture 5 13,367 — Leasehold improvements 5 347,809 216,984 Computer equipment 3 53,060 1,329 818,864 321,560 Less accumulated depreciation (74,042 ) (22,650 ) Property and equipment, net $ 744,822 $ 298,910

Lease Liabilities and Right o_2

Lease Liabilities and Right of Use Assets (Tables)	12 Months Ended
	Sep. 30, 2020
Leases [Abstract]
Schedule of Financing Right-of-use Assets	Financing lease right-of-use assets (“Financing ROU”) is summarized below: September 30, 2020 2019 Financing ROU assets $ 231,841 $ 231,841 Less accumulated depreciation (74,150 ) (27,782 ) Balance of Financing ROU assets $ 157,691 $ 204,059
Schedule of Financing Lease Liability	Financing lease liability related to the Financing ROU assets is summarized below: September 30, 2020 2019 Financing lease payables for equipment $ 231,841 $ 231,841 Total financing lease payables 231,841 231,841 Payments of financing lease liabilities (53,491 ) (18,395 ) Total 178,350 213,446 Less: short term portion (42,234 ) (35,096 ) Long term portion $ 136,116 $ 178,350
Schedule of Future Minimum Lease Payments of Financing Lease	Future minimum lease payments under the financing lease agreements at September 30, 2020 are as follows: Years ending September 30, Amount 2021 $ 61,266 2022 61,266 2023 53,787 2024 40,875 2025 4,185 Total minimum financing lease payments 221,379 Less: discount to fair value (43,029 ) Total financing lease payable at September 30, 2020 $ 178,350
Schedule of Operating Right-of-use Assets	Operating right-of-use asset (“ROU”) is summarized below: September 30, 2020 Operating office lease $ 231,337 Less accumulated reduction (25,134 ) Balance of ROU asset as of September 30, 2020 $ 206,203
Schedule of Operating Lease Liability	Operating lease liability related to the ROU asset is summarized below: September 30, 2020 Operating office lease $ 231,337 Total lease liabilities 231,337 Reduction of lease liability (18,501 ) Total 212,836 Less: short term portion as of September 30, 2020 (35,943 ) Long term portion as of September 30, 2020 $ 176,893
Schedule of Future Minimum Lease Payments of Operating Lease	Future base lease payments under the non-cancellable operating lease at September 30, 2020 are as follows: Years ending September 30, Amount 2021 $ 59,576 2022 61,382 2023 63,236 2024 65,137 2025 27,474 Total minimum non-cancellable operating lease payments 276,805 Less: discount to fair value (63,969 ) Total lease liability at September 30, 2020 $ 212,836

Related-Party Transactions (Tab

Related-Party Transactions (Tables)	12 Months Ended
	Sep. 30, 2020
Related Party Transactions [Abstract]
Schedule of Amounts Due to Related Parties	At September 30, 2020 and 2019, amounts due to related parties consisted of the following: September 30, 2020 2019 Consulting fee – related party $ — $ 160,000 Advances from related parties — 20,000 Total $ — $ 180,000

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	12 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Schedule of Warrant Activities	Warrants activities for the year ended September 30, 2020 is summarized as follows: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Warrants Price Term (Years) Value Balance Outstanding at September 30, 2019 — $ — — $ — Warrants issued in connection with the sale of 7 shares of Series D-1 Preferred Stock 656,674,588 $ 0.002 4.2 $ — Deemed issuance in connection with the asset sale and recapitalization transaction (see Note 3) 200,000,000 $ 0.003 4.9 $ — Balance Outstanding at September 30, 2020 856,674,588 $ 0.002 4.3 $ — Exercisable at September 30, 2020 656,674,588 $ 0.002 4.2 $ —

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate	The items accounting for the difference between income taxes at the effective statutory rate and the provision for income taxes for the fiscal years ended September 30, 2020 and 2019 are as follow: Years Ended September 30, 2020 2019 Income tax benefit at U.S. statutory rate of 21%  $ (665,756 ) $ (335,595 ) Income tax benefit – state (146,783 ) (73,980 ) Non-deductible expenses (53,244 ) 10,483 Change in valuation allowance 865,783 399,402 Total provision for income tax $ — $ —
Schedule of Deferred Tax Assets	The Company’s approximate net deferred tax asset as of September 30, 2020 and 2019 was as follow: Years Ended September 30, 2020 2019 Net operating loss carry-forwards $ 9,790,195 $ 8,924,412 Total deferred tax asset 9,790,195 8,924,412 Less: valuation allowance (9,790,195 ) (8,924,412 ) Net deferred tax asset $ — $ —

Organization and Nature of Op_2

Organization and Nature of Operations (Details Narrative) - $ / shares	Sep. 24, 2020	Sep. 22, 2020	Jun. 05, 2020	May 18, 2020	Sep. 24, 2021	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2021	Sep. 15, 2020
Common stock, shares authorized						12,000,000,000	12,000,000,000
Asset sale transaction percentage			54.55%
Preferred stock, shares authorized						26,667	26,667
Preferred stock, par value						$ 0.0001	$ 0.0001
Common stock, par value						$ 0.0001	$ 0.0001
Minimum [Member]
Common stock, shares authorized		6,666,667
Common stock, par value		$ 0.0001
Maximum [Member]
Common stock, shares authorized		12,000,000,000
Common stock, par value		$ 0.0001
Common Stock [Member]
Number of shares issued during period
Conversion of common stock shares converted	5,081,550,620
Common Stock [Member] | Minimum [Member]
Common stock, shares authorized		6,666,667
Common stock, par value		$ 0.0001
Common Stock [Member] | Maximum [Member]
Common stock, shares authorized		12,000,000,000
Common stock, par value		$ 0.0001
Series D-1 Preferred Stock [Member]
Common stock, shares authorized				6,666,667
Conversion of common stock shares converted					5,081,550,620	656,674,588
Preferred stock, shares authorized		1,000
Preferred stock, par value				$ 0.0001
Common stock, par value				$ 0.0001
Series D-1 Preferred Stock [Member] | Minimum [Member]
Common stock, shares authorized				6,666,667
Series D-1 Preferred Stock [Member] | Maximum [Member]
Common stock, shares authorized				12,000,000,000
Series D-1 Preferred Stock [Member] | Common Stock [Member]
Conversion of common stock shares converted	1,000	5,081,550,620
Series E Preferred Stock [Member]
Preferred stock, shares authorized									2,000
Preferred stock, par value									$ 0.0001
Stated value of preferred stock									$ 2,000
Series D-2 Preferred Stock [Member]
Number of shares issued during period
Conversion of common stock shares converted				10,000	41,216,000
Preferred stock, shares authorized		4,121.6				4,360	4,360
Preferred stock, par value				$ 0.0001		$ 0.0001	$ 0.0001
Common stock, par value				$ 4,360
Series D-2 Preferred Stock [Member] | Minimum [Member]
Common stock, shares authorized				6,666,667
Series D-2 Preferred Stock [Member] | Maximum [Member]
Common stock, shares authorized				12,000,000,000
Series D-2 Preferred Stock [Member] | Common Stock [Member]
Conversion of common stock shares converted	41,216,000	41,216,000
Series F Preferred Stock [Member] | Subsequent Event [Member]
Preferred stock, shares authorized								1,000
Preferred stock, par value								$ 0.0001
Stated value of preferred stock								$ 2,000
Asset Purchase Agreement [Member]
Acquisition percentage of issued and outstanding			54.55%
Asset sale transaction percentage						54.55%
Asset Purchase Agreement [Member] | Common Stock [Member]
Conversion of common stock shares converted			5,081,550,620			5,081,550,620
Asset Purchase Agreement [Member] | Series D-1 Preferred Stock [Member]
Number of shares issued during period			1,000
Acquisition percentage of issued and outstanding			54.55%
Common stock, shares authorized			6,666,667			12,000,000,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2018
Net loss	$ (3,170,267)	$ (1,597,834)
Net cash used in operations	(3,470,755)	(1,119,881)
Accumulated deficit	(43,187,588)	(38,011,201)
Stockholders' equity	(307,595)	(632,360)	$ (812,545)
Working capital deficit	877,234
Cash balances in excess of FDIC insured	1,538,951	310,407
Revenues	181,229
Uncertain tax portion
Interest and penalties
Allowance for doubtful accounts		0
Accrued liabilities	$ 56,728	48,241
Other Receivables [Member]
Accounts receivable		4,000
Accrued Director Compensation [Member]
Accrued liabilities		$ 70,000
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Concentration percentage	56.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer Two [Member]
Concentration percentage	44.00%
Minimum [Member]
Estimated useful lives	3 years
Maximum [Member]
Estimated useful lives	5 years

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Anti-dilutive Shares Outstanding (Details) - shares	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Total antidilutive securities excluded from computation of earnings per share	2,568,851,829	4,392,557,509
Stock Warrants [Member]
Total antidilutive securities excluded from computation of earnings per share	856,674,588
Series C-1 Preferred Stock [Member]
Total antidilutive securities excluded from computation of earnings per share	445,301,289
Series C-2 Preferred Stock [Member]
Total antidilutive securities excluded from computation of earnings per share	733,542,619
Series D-1 Preferred Stock [Member]
Total antidilutive securities excluded from computation of earnings per share		4,392,557,509
Series E Preferred Stock [Member]
Total antidilutive securities excluded from computation of earnings per share	533,333,333

Asset Sale and Recapitalizati_3

Asset Sale and Recapitalization Transaction (Details Narrative) - USD ($)	Sep. 24, 2020	Sep. 22, 2020	Jun. 05, 2020	Sep. 24, 2021	Sep. 30, 2020	Sep. 30, 2019	May 18, 2020
Common stock, shares authorized					12,000,000,000	12,000,000,000
Asset sale transaction percentage			54.55%
Unrealized gain on exchange rate					$ 49,202
Discontinued operations written-off					$ 158,852
Common Stock [Member]
Number of shares issued during period
Conversion of common stock shares converted	5,081,550,620
Series D-1 Preferred Stock [Member]
Common stock, shares authorized							6,666,667
Conversion of common stock shares converted				5,081,550,620	656,674,588
Sale of share issued on consideration			1,000
Fair value of asset acquired			$ 246,656
Series D-1 Preferred Stock [Member] | Common Stock [Member]
Conversion of common stock shares converted	1,000	5,081,550,620
Asset Purchase Agreement [Member]
Acquisition percentage of issued and outstanding			54.55%
Asset sale transaction percentage					54.55%
Asset Purchase Agreement [Member] | Common Stock [Member]
Conversion of common stock shares converted			5,081,550,620		5,081,550,620
Asset Purchase Agreement [Member] | Series D-1 Preferred Stock [Member]
Number of shares issued during period			1,000
Acquisition percentage of issued and outstanding			54.55%
Common stock, shares authorized			6,666,667		12,000,000,000

Asset Sale and Recapitalizati_4

Asset Sale and Recapitalization Transaction - Schedule of Assets and Liabilities in Transaction (Details)	Sep. 30, 2020USD ($)
Business Combination and Asset Acquisition [Abstract]
Cash	$ 675,928
Prepaid expense and other current assets	17,539
Total assets acquired	693,467
Accounts payable and other liabilities	(40,149)
Liabilities of discontinued operations	(406,662)
Total liabilities assumed	(446,811)
Net assets acquired	$ 246,656

Marketable Securities (Details

Marketable Securities (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2017
Unrealized loss on marketable securities	$ 6,900	$ 15,800
Marketable securities	$ 11,100	$ 18,000
Amarantus BioScience Holdings, Inc. [Member]
Number of shares on acquisition			1,000,000
Fair value of acquisition			$ 40,980

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 51,392	$ 20,160

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Laboratory equipment	$ 404,628	$ 103,247
Furniture	13,367
Leasehold improvements	347,809	216,984
Computer equipment	53,060	1,329
Property and equipment, gross	818,864	321,560
Less accumulated depreciation	(74,042)	(22,650)
Property and equipment, net	$ 744,822	$ 298,910
Laboratory Equipment [Member]
Estimated Useful Life in Years	5 years
Furniture [Member]
Estimated Useful Life in Years	5 years
Leasehold Improvements [Member]
Estimated Useful Life in Years	5 years
Computer Equipment [Member]
Estimated Useful Life in Years	3 years

Debt (Details Narrative)

Debt (Details Narrative) - USD ($)	Sep. 30, 2019	Jun. 25, 2018	May 25, 2018	May 25, 2018	Jul. 28, 2017	Jul. 28, 2017	Oct. 28, 2016	Sep. 30, 2017	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2018
Conversion of preferred stock, value
Note Payable One [Member]
Convertible notes payable							$ 20,000
Debt instrument, interest							12.00%
Proceeds from notes payable							$ 20,000
Debt instrument, description							Note I bears an interest rate of 12% per year (which interest rate shall be increased to 18% per year upon the occurrence of an Event of Default (as defined in Note I)), matured on April 28, 2017 and the principal and interest are convertible at any time at a conversion price equal to the lower of $0.25 or closing price on the date of the conversion, provided, however, that if an event of default has occurred, regardless of whether such Event of Default has been cured or remains ongoing, the Note I shall be convertible at 65% of the lowest VWAP , as reported on the OTCQB or other principal trading market, during the prior twenty trading days (the "Default Conversion Price"). The purchaser may not convert the Note to the extent that such conversion would result in beneficial ownership by a purchaser and its affiliates of more than 4.99% of the Company's issued and outstanding common stock. Note I may be prepaid, in whole or in part, at any time upon five-days written notice to the holder at an amount equal to (i) 110% of the outstanding principal prepayment amount during the first 30 days after the execution of Note I; (ii) 115% of the outstanding principal prepayment amount if paid between the 31st to 60th day after the execution of Note I; (iii) 120% of the outstanding principal prepayment amount if paid between the 61st to 90th day after the execution of Note I and; (iv) 125% of the outstanding principal prepayment amount if paid after the 91st day after the execution of Note I.
Debt instrument, maturity date							Apr. 28, 2017
Note Payable One [Member] | Maximum [Member]
Debt instrument, interest							18.00%
Note Payable Two [Member]
Contingent liabilities									40,000
Note Payable Two [Member] | Maximum [Member]
Debt instrument accrued interest payable									64,040
Note Payable Two [Member] | Minimum [Member]
Debt instrument accrued interest payable									24,040
Common Stock [Member]
Conversion of preferred stock, value									508,155
Series A Preferred Stock [Member]
Conversion of preferred stock, value
Coastal Investment Partners LLC [Member]
Debt instrument, interest			8.00%	8.00%
Debt instrument due month			18 months
Debt instrument, conversion rate			9.99%
Convertible debt outstanding amount	$ 192,832									$ 192,832
Debt instrument accrued interest payable	20,783
Coastal Investment Partners LLC [Member] | Common Stock [Member]
Debt instrument convertible conversion price per share			$ 0.015	$ 0.015
Coastal Exchange Agreement [Member] | Coastal Investment Partners LLC [Member]
Convertible notes payable			$ 305,664	$ 305,664
Convertible debt outstanding amount									192,832
Debt instrument accrued interest payable									24,383
Coastal Exchange Agreement [Member] | Coastal Investment Partners LLC [Member] | Series A Preferred Stock [Member]
Conversion of preferred stock, shares			192,832
Conversion of preferred stock, value			$ 192,832
Black Mountain Exchange Agreement [Member] | Black Mountain Equity Partners LLC [Member]
Convertible notes payable			$ 25,000	$ 25,000
Debt instrument, interest			12.00%	12.00%
Debt instrument due month			12 months
Repayment of debt			$ 5,000							7,500	$ 10,000
Convertible debt outstanding amount	7,500								0	7,500
Exchange Agreement [Member] | Note Payable One [Member]
Debt instrument, interest					10.00%	10.00%
Debt instrument convertible conversion price per share					$ 0.06	$ 0.06
Convertible debt outstanding amount	20,000								20,000	20,000
Debt instrument accrued interest payable									12,020	8,420
Contingent liabilities									32,020
Debt instrument original issue discount					$ 5,600
Exchange Agreement [Member] | Promissory Note [Member]
Repayment of debt										24,000	$ 6,000
Exchange Agreement [Member] | Promissory Note [Member] | New 2016 Investor Note [Member]
Convertible notes payable			$ 47,259	$ 47,259
Debt instrument, interest			12.00%	12.00%
Debt instrument due month				24 months
Convertible debt outstanding amount	17,259									17,259
Debt instrument accrued interest payable									6,587	6,587
Debt instrument periodic payment		$ 2,000
Note Two Agreement [Member] | Note Payable Two [Member]
Convertible notes payable					$ 20,000	$ 20,000
Debt instrument, interest					10.00%	10.00%	12.00%
Debt instrument convertible conversion price per share					$ 0.06	$ 0.06
Convertible debt outstanding amount	$ 20,000						$ 20,000		20,000	20,000
Debt instrument accrued interest payable									12,020	$ 8,420
Proceeds from notes payable							$ 20,000
Debt instrument, description							Note II bears an interest rate of 12% per year (which interest rate shall be increased to 18% per year upon the occurrence of an Event of Default (as defined in Note II)), matured on April 28, 2017 and the principal and interest are convertible at any time at a conversion price equal to the lower of $0.25 or closing price on the date of the conversion, provided, however, that if an event of default has occurred, regardless of whether such Event of Default has been cured or remains ongoing, Note II shall be convertible at 65% of the lowest VWAP, as reported on the OTCQB or other principal trading market, during the prior twenty trading days (the "Default Conversion Price"). The purchaser may not convert Note II to the extent that such conversion would result in beneficial ownership by a purchaser and its affiliates of more than 4.99% of the Company's issued and outstanding common stock. Note II may be prepaid, in whole or in part, at any time upon five-days written notice to the holder at an amount equal to (i) 110% of the outstanding principal prepayment amount during the first 30 days after the execution of Note II; (ii) 115% of the outstanding principal prepayment amount if paid between the 31st to 60th day after the execution of Note II; (iii) 120% of the outstanding principal prepayment amount if paid between the 61st to 90th day after the execution of Note II and; (iv) 125% of the outstanding principal prepayment amount if paid after the 91st day after the execution of Note II.
Debt instrument, maturity date						Apr. 28, 2017
Contingent liabilities									$ 32,020
Debt instrument affiliates percentage							4.99%
Purchase price value						$ 20,000
Debt instrument original issue discount						$ 5,600
Note Two Agreement [Member] | Note Payable Two [Member] | Maximum [Member]
Debt instrument, interest					18.00%	18.00%	18.00%
Note Two Agreement [Member] | Note Payable Two [Member] | Minimum [Member]
Debt instrument, interest					10.00%	10.00%	12.00%
Debt instrument convertible conversion price per share							$ 0.25
Loan Agreement [Member]
Debt instrument, interest									33.30%
Debt instrument principal amount									$ 1,000
Loan Agreement [Member] | Maximum [Member]
Debt instrument accrued interest payable								$ 1,022
Loan Agreement [Member] | Minimum [Member]
Debt instrument accrued interest payable								$ 1,000

Lease Liabilities and Right o_3

Lease Liabilities and Right of Use Assets (Details Narrative) - USD ($)	1 Months Ended					12 Months Ended
	Jan. 31, 2020	Dec. 31, 2019	Aug. 31, 2019	Mar. 31, 2019	Nov. 30, 2018	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Lease description						The lease is for a period of 60 months commencing in February 2020 and expiring in February 2025.
Depreciation expense financing ROU asset						$ 46,368	$ 27,380
Right-of-use assets						206,203
Lease liabilities						212,836		$ 212,836
Lease cost						34,147
Base lease cost						18,501
Lease other expense						$ 15,646
Operating discount rates						12.00%
Accounting Standards Update 2016-02 [Member]
Right-of-use assets						$ 231,337
Lease liabilities						$ 231,337
Minimum [Member]
Finance discount rates						8.00%
Maximum [Member]
Finance discount rates						15.00%
Financing Agreement [Member] | First Lessor [Member]
Monthly base rent					$ 379
Lease term					60 months
Lease expiration					Oct. 31, 2023
Lease description					60 months commencing in November 2018 through October 2023.
Financing lease payable					$ 16,064
Financing Agreement [Member] | Second Lessor [Member]
Monthly base rent					$ 1,439
Lease term					60 months
Lease expiration					Oct. 31, 2023
Lease description					60 months commencing in November 2018 through October 2023.
Financing lease payable					$ 62,394
Financing Agreement [Member] | Third Lessor [Member]
Monthly base rent				$ 1,496
Lease term									60 months
Lease expiration				Oct. 31, 2023
Lease description				60 months commencing in March 2019 through April 2024.
Financing lease payable				$ 64,940
Financing Agreement [Member] | Fourth Lessor [Member]
Monthly base rent			$ 397
Lease term			60 months
Lease expiration			Oct. 31, 2023
Lease description			60 months commencing in August 2019 through August 2024.
Financing lease payable			$ 19,622
Financing Agreement [Member] | Fifth Lessor [Member]
Monthly base rent	$ 1,395
Lease term	60 months
Lease expiration	Oct. 31, 2023
Lease description	60 months commencing in January 2020 through December 2024.
Financing lease payable	$ 68,821
Lease Agreement [Member]
Lease term		60 months
Lease expiration		Feb. 28, 2025
Lease description		The lease is for a period of 60 months, with options to continue leasing, commencing in February 2020 and expiring in February 2025.
Lease Agreement [Member] | First Year [Member]
Monthly base rent		$ 4,878
Lease Agreement [Member] | Second Year [Member]
Monthly base rent		5,026
Lease Agreement [Member] | Third Year [Member]
Monthly base rent		5,179
Lease Agreement [Member] | Fourth Year [Member]
Monthly base rent		5,335
Lease Agreement [Member] | Fifth Year [Member]
Monthly base rent		$ 5,495

Lease Liabilities and Right o_4

Lease Liabilities and Right of Use Assets - Schedule of Financing Right-of-use Assets (Details) - USD ($)	Sep. 30, 2020	Sep. 30, 2019
Leases [Abstract]
Financing ROU asset	$ 231,841	$ 231,841
Less accumulated depreciation	(74,150)	(27,782)
Balance of Financing ROU assets	$ 157,691	$ 204,059

Lease Liabilities and Right o_5

Lease Liabilities and Right of Use Assets - Schedule of Financing Lease Liability (Details) - USD ($)	Sep. 30, 2020	Sep. 30, 2019
Leases [Abstract]
Financing lease payables for equipment	$ 231,841	$ 231,841
Total financing lease payables	231,841	231,841
Payments of financing lease liabilities	(53,491)	(18,395)
Total	178,350	213,446
Less: short term portion	(42,234)	(35,096)
Long term portion	$ 136,116	$ 178,350

Lease Liabilities and Right o_6

Lease Liabilities and Right of Use Assets - Schedule of Future Minimum Lease Payments of Financing Lease (Details) - USD ($)	Sep. 30, 2020	Sep. 30, 2019
Leases [Abstract]
2021	$ 61,266
2022	61,266
2023	53,787
2024	40,875
2025	4,185
Total minimum financing lease payments	221,379
Less: discount to fair value	(43,029)
Total financing lease payable at September 30, 2020	$ 178,350	$ 213,446

Lease Liabilities and Right o_7

Lease Liabilities and Right of Use Assets - Schedule of Operating Right-of-use Assets (Details) - USD ($)	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2019
Leases [Abstract]
Operating office lease	$ 231,337	$ 231,337
Less accumulated reduction	(25,134)
Balance of ROU asset as of September 30, 2020	$ 206,203

Lease Liabilities and Right o_8

Lease Liabilities and Right of Use Assets - Schedule of Operating Lease Liability (Details) - USD ($)	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2019
Leases [Abstract]
Operating office lease	$ 231,337	$ 231,337
Total lease liabilities		231,337
Reduction of lease liability		(18,501)
Total	212,836	212,836
Less: short term portion as of September 30, 2020	(35,943)	(35,943)
Long term portion as of September 30, 2020	$ 176,893	$ 176,893

Lease Liabilities and Right o_9

Lease Liabilities and Right of Use Assets - Schedule of Future Minimum Lease Payments of Operating Lease (Details) - USD ($)	Sep. 30, 2020	Jun. 30, 2020
Leases [Abstract]
2021	$ 59,576
2022	61,382
2023	63,236
2024	65,137
2025	27,474
Total minimum non-cancellable operating lease payments	276,805
Less: discount to fair value	(63,969)
Total lease liability at September 30, 2020	$ 212,836	$ 212,836

Related-Party Transactions (Det

Related-Party Transactions (Details Narrative) - USD ($)	Jul. 03, 2019	Feb. 08, 2019	Dec. 31, 2018	Oct. 26, 2018	Oct. 17, 2018	Sep. 30, 2020	Sep. 30, 2019	Jun. 05, 2020
Proceeds from sale of preferred stock						$ 4,590,000	$ 1,599,469
Consulting fee due to related party							160,000
Advances from related parties							20,000
Due to related parties							180,000
Series D-1 Preferred Stock [Member]
Proceeds from sale of preferred stock						2,590,000	$ 1,599,469
Consulting fee due to related party						$ 160,000
Conversion price						$ 0.24
Advances from related parties						$ 20,000
Securities Purchase Agreement [Member] | Henry Cole [Member] | Series D-1 Preferred Stock [Member]
Proceeds from sale of preferred stock					$ 20,000
Securities Purchase Agreement [Member] | Dr. Rajesh Shrotriya [Member] | Series D-1 Preferred Stock [Member]
Proceeds from sale of preferred stock			$ 50,000	$ 100,000
Securities Purchase Agreement [Member] | Jeffrey Stephens [Member] | Series D-1 Preferred Stock [Member]
Proceeds from sale of preferred stock		$ 35,000
Securities Purchase Agreement [Member] | Matthew Schwartz [Member] | Series D-1 Preferred Stock [Member]
Proceeds from sale of preferred stock	$ 250,000
Asset Sale and Recapitalization Transaction [Member] | Series D-1 Preferred Stock [Member]
Proceeds from sale of preferred stock	$ 455,000
Consulting Agreement [Member] | Mr. Kucharchuk [Member]
Compensation to related party								$ 15,000

Related-Party Transactions - Sc

Related-Party Transactions - Schedule of Amounts Due to Related Parties (Details) - USD ($)	Sep. 30, 2020	Sep. 30, 2019
Related Party Transactions [Abstract]
Consulting fee - related party		$ 160,000
Advances from related parties		20,000
Total		$ 180,000

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative)	Jun. 05, 2021shares	Sep. 24, 2020shares	Sep. 22, 2020$ / sharesshares	Sep. 16, 2020USD ($)shares	Sep. 15, 2020USD ($)$ / sharesshares	May 18, 2020$ / sharesshares	Aug. 20, 2015shares	Sep. 24, 2021shares	Sep. 30, 2020USD ($)$ / sharesshares	Sep. 30, 2019USD ($)$ / sharesshares	Jun. 05, 2020USD ($)$ / sharesshares	Mar. 07, 2017$ / sharesshares	Feb. 18, 2011shares
Common stock, shares authorized									12,000,000,000	12,000,000,000
Common stock, par value | $ / shares									$ 0.0001	$ 0.0001
Preferred stock, shares authorized									26,667	26,667
Preferred stock, par value | $ / shares									$ 0.0001	$ 0.0001
Stock issued for services | $										$ 100
Consulting fee due to related party | $										160,000
Proceeds from sale of stock | $									$ 4,590,000	$ 1,599,469
Stock issued									1,000
Aggregate investment amount | $									$ 2,000,000
Common stock, shares issued									5,124,164,690
Common stock, shares outstanding									5,124,164,690
Stock Option [Member]
Number of option granted
Common stock were be reserved for issuance under the plan		3,043,638,781
Fair market value of share on grant date percentage									110.00%
Number of stock options issued and outstanding
2011 Stock Option Plan [Member]
Number of option authorized to purchase common stock													57
Asset Sale Transaction and Recapitalization [Member]
Common stock, shares issued											1,398,070
Common Stock [Member]
Stock issued for services, shares
Stock issued for services | $
Conversion of common stock shares converted		5,081,550,620
Number of shares issuable	1,398,070
Common stock, shares outstanding									5,124,164,690
Common stock, shares unissed									5,122,766,620
Stock Warrants [Member]
Warrants issued									856,674,588		656,674,588
Warrants exercise price per share | $ / shares											$ 0.0025
Warrant maturity date											Nov. 27, 2024
Warrants outstanding									856,674,588
Two Investors [Member] | Stock Warrants [Member]
Warrants issued											200,000,000
Warrants exercise price per share | $ / shares											$ 0.0025
Market capitalization | $											$ 50,000,000
Warrant term											5 years
Series A Preferred Stock [Member]
Preferred stock designated							1,333
Preferred stock, shares authorized							26,667		1,333	1,333
Stockholder voting rights							Each holder of Series A Preferred Stock is entitled to 500 votes for each share of Series A Preferred Stock held as of the applicable date on any matter that is submitted to a vote or for the consent of the stockholders of the Company. The holders of Series A Preferred Stock shall have no special voting rights and their consent is not required (except to the extent they are entitled to vote with holders of Common Stock as set forth herein) for the taking of any corporate action.
Preferred stock, shares issued									667		667
Preferred stock, shares outstanding									667
Preferred stock, par value | $ / shares									$ 0.0001	$ 0.0001
Stock issued for services, shares
Stock issued for services | $
Series A Preferred Stock [Member] | Board of Directors [Member]
Preferred stock, shares issued									667
Preferred stock, shares outstanding									667
Series B Preferred Stock [Member]
Preferred stock designated												10,523
Preferred stock, shares issued
Preferred stock, shares outstanding
Preferred stock, par value | $ / shares												$ 0.0001
Preferred stock stated value | $ / shares												$ 0.0001
Series C-1 Preferred Stock [Member]
Preferred stock designated						3,000
Preferred stock, shares issued									2,966.2212		2,966.2212
Preferred stock, shares outstanding									2,966.2212
Preferred stock, par value | $ / shares						$ 0.0001
Preferred stock stated value | $ / shares						$ 4,128.42
Preferred stock description						Each share of Series C-1 Preferred Stock is convertible into shares of common stock any time after the Initial Issuance Date at a conversion price of $0.0275 per share. The number of shares of common stock issuable upon conversion shall be determined by dividing (x) the conversion amount (determined by the sum of the stated value thereof plus any additional amount thereon which consist of all dividends, whether declared or not) of such share of Series C-1 by (y) the conversion price of $0.0275 per share (subject to temporary adjustment upon a triggering event as defined by the Series C-1 Certificate of Designation, to 80% of the conversion price). The adjusted conversion price is only in effect until the triggering event is cured. The convertibility of shares of Series C-1 Preferred Stock is limited such that a holder of Series C-1 Preferred Stock may not convert Series C-1 Preferred Stock to common stock to the extent that the number of shares of common stock to be issued pursuant to such conversion, when aggregated with all other shares of common stock owned by the holder at such time, would result in the holder beneficially owning (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934) more than 4.99% of all of the Company's common stock outstanding.
Conversion price | $ / shares						$ 0.0275
Conversion percentage						0.80
Series C-2 Preferred Stock [Member]
Preferred stock designated						6,000
Preferred stock, shares authorized									6,000	6,000
Preferred stock, shares issued									4,917		4,916.865
Preferred stock, shares outstanding									4,917
Preferred stock, par value | $ / shares						$ 0.0001			$ 0.0001	$ 0.0001
Preferred stock stated value | $ / shares						$ 410.27
Preferred stock description						Each share of Series C-2 Preferred Stock is convertible into shares of common stock any time after the initial issuance date at a conversion price of $0.00275 per share. The number of shares of common stock issuable upon conversion shall be determined by dividing (x) the conversion amount (determined by the sum of the stated value thereof plus any additional amount thereon) of such share of Series C-2 by (y) the conversion price of $0.00275 per share (subject to temporary adjustment upon a triggering event as defined by the Series C-2 Certificate of Designation to 80% of the conversion price). The adjusted conversion price is only in effect until the triggering event is cured. The convertibility of shares of Series C-2 Preferred Stock is limited such that a holder of Series C-2 Preferred Stock may not convert Series C-2 Preferred Stock to common stock to the extent that the number of shares of common stock to be issued pursuant to such conversion, when aggregated with all other shares of common stock owned by the holder at such time, would result in the holder beneficially owning (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934) more than 4.99% of all of the Company's common stock outstanding.
Conversion price | $ / shares						$ 0.00275
Stock issued for services, shares
Stock issued for services | $
Series D-1 Preferred Stock [Member]
Common stock, shares authorized						6,666,667
Common stock, par value | $ / shares						$ 0.0001
Preferred stock designated						1,000
Preferred stock, shares authorized			1,000
Preferred stock, par value | $ / shares						$ 0.0001
Preferred stock stated value | $ / shares						$ 9,104.89
Conversion price | $ / shares									$ 0.24
Conversion percentage						0.5455
Pro-rata description						Each share of Series D-1 Preferred Stock is convertible into a pro rata portion of 54.55% of the Fully Diluted Equity (as defined in the Series D-1 Certificate of Designation) of the Company upon the effectiveness of the amendment to the Company's Articles of Incorporation to increase the Company's authorized common stock, par value $0.0001 per share, from 6,666,667 shares to 12,000,000,000 shares, which occurred on September 24, 2020 ( the "Conversion Date").
Stock issued for services, shares										26
Stock issued for services | $										$ 100
Stock issued related parties, shares										5
Conversion of debt amount | $									$ 459,153
Consulting fee due to related party | $									160,000
Proceeds from sale of stock | $									$ 2,590,000	$ 1,599,469
Conversion of common stock shares converted								5,081,550,620	656,674,588
Converted shares issued								1,000
Series D-1 Preferred Stock [Member] | Common Stock [Member]
Conversion of common stock shares converted		1,000	5,081,550,620
Series D-1 Preferred Stock [Member] | Related Parties [Member]
Proceeds from sale of stock | $										$ 455,000
Series D-2 Preferred Stock [Member]
Common stock, par value | $ / shares						$ 4,360
Preferred stock, shares authorized			4,121.6						4,360	4,360
Preferred stock, shares issued		4,121.64									4,121.64
Preferred stock, shares outstanding
Preferred stock, par value | $ / shares						0.0001			$ 0.0001	$ 0.0001
Preferred stock stated value | $ / shares						$ 500
Stock issued for services, shares
Stock issued for services | $
Conversion of common stock shares converted						10,000		41,216,000
Converted shares issued								4,121.64
Series D-2 Preferred Stock [Member] | Common Stock [Member]
Conversion of common stock shares converted		41,216,000	41,216,000
Series E Preferred Stock [Member]
Preferred stock, shares authorized					2,000
Preferred stock, shares issued									1,000
Preferred stock, shares outstanding									1,000
Preferred stock, par value | $ / shares					$ 0.0001
Preferred stock stated value | $ / shares					$ 2,000
Preferred stock description					Each share of Series E Preferred Stock is convertible into shares of common stock any time after the initial issuance date at the Conversion Price which is the lesser of: (i) $0.00375 or (ii) 75% of the average closing price of the common stock during the prior five trading days on the principal market, subject to adjustment as provided in the Series E Certificate of Designation. Provided, however, the Conversion Price shall never be less than $0.0021. The number of shares of common stock issuable upon conversion shall be determined by multiplying the number of outstanding shares by the stated value per share of $2,000 plus accrued dividends and dividing that number by (y) the Conversion Price.
Conversion price | $ / shares					$ 0.00375
Conversion percentage					0.75
Conversion of debt amount | $					$ 2,000
Beneficial conversion feature amount | $									$ 2,000,000
Stock dividend | $									$ 6,120
Series E Preferred Stock [Member] | Securities Purchase Agreement [Member]
Preferred stock description				The Company's Series E Preferred Stock has a stated value of $2,000 per share and shall accrue, on a quarterly basis in arrears, dividends at the rate of 8% per annum on the stated value. The dividends shall be paid quarterly at the option of the holder of the Series E Preferred in either cash or shares of common stock of the Company. The Series E Preferred is convertible two days after the increase the Company's authorized common stock which became effective on September 24, 2020. The number of shares of common stock issuable on the conversion of the Series E Preferred is determined by dividing the stated value of the number of shares being converted, plus any accrued and unpaid dividends, by the lesser of: (i) $0.00375 and (ii) 75% of the average closing price of the Company's common stock during the prior five trading days; provided, however, the conversion price shall never be less than $0.0021. For eighteen months from the anniversary of the closing, the Company needs to obtain consent from several of investors prior to engaging in any future capital raises.
Stock issued				1,000
Aggregate investment amount | $				$ 2,000,000
Minimum [Member]
Common stock, shares authorized			6,666,667
Common stock, par value | $ / shares			$ 0.0001
Minimum [Member] | Common Stock [Member]
Common stock, shares authorized			6,666,667
Common stock, par value | $ / shares			$ 0.0001
Minimum [Member] | Series C-1 Preferred Stock [Member]
Conversion price | $ / shares						$ 0.0275
Minimum [Member] | Series D-1 Preferred Stock [Member]
Common stock, shares authorized						6,666,667
Minimum [Member] | Series D-2 Preferred Stock [Member]
Common stock, shares authorized						6,666,667
Minimum [Member] | Series E Preferred Stock [Member]
Conversion price | $ / shares					$ 0.0021
Maximum [Member]
Common stock, shares authorized			12,000,000,000
Common stock, par value | $ / shares			$ 0.0001
Maximum [Member] | Common Stock [Member]
Common stock, shares authorized			12,000,000,000
Common stock, par value | $ / shares			$ 0.0001
Maximum [Member] | Board of Directors [Member] | 2011 Stock Option Plan [Member]
Number of option authorized to purchase common stock													14
Maximum [Member] | Series C-1 Preferred Stock [Member]
Common stock outstanding, percentage						4.99%
Maximum [Member] | Series C-2 Preferred Stock [Member]
Common stock outstanding, percentage						4.99%
Maximum [Member] | Series D-1 Preferred Stock [Member]
Common stock, shares authorized						12,000,000,000
Maximum [Member] | Series D-2 Preferred Stock [Member]
Common stock, shares authorized						12,000,000,000

Stockholders' Deficit - Schedul

Stockholders' Deficit - Schedule of Warrant Activities (Details) - Stock Warrants [Member]	12 Months Ended
	Sep. 30, 2020USD ($)$ / sharesshares
Number of Warrants, Outstanding Beginning balance | shares
Number of Warrants, Warrants issued in connection with the sale of Series D-1 preferred stock | shares	656,674,588
Number of Warrants, Deemed issuance in connection with the asset sale and recapitalization transaction (see Note 3) | shares	200,000,000
Number of Warrants, Outstanding Ending balance | shares	856,674,588
Number of Warrants, Exercisable | shares	856,674,588
Weighted Average Exercise Price, Outstanding Beginning balance | $ / shares
Weighted Average Exercise Price, Warrants issued in connection with the sale of Series D-1 preferred stock | $ / shares	0.002
Weighted Average Exercise Price, Deemed issuance in connection with the asset sale and recapitalization transaction (see Note 3) | $ / shares	0.003
Weighted Average Exercise Price, Outstanding Ending balance | $ / shares	0.002
Weighted Average Exercise Price, Exercisable | $ / shares	$ 0.002
Weighted Average Remaining Contractual Term (Years), Beginning Balance Outstanding	0 years
Weighted Average Remaining Contractual Term (Years), Warrants issued in connection with the sale of Series D-1 preferred stock	4 years 2 months 12 days
Weighted Average Remaining Contractual Term (Years), Deemed issuance in connection with the asset sale and recapitalization transaction (see Note 3)	4 years 10 months 25 days
Weighted Average Remaining Contractual Term (Years), Ending Balance Outstanding	4 years 3 months 19 days
Weighted Average Remaining Contractual Term (Years), Exercisable	4 years 2 months 12 days
Aggregate Intrinsic Value, Beginning Balance Outstanding | $
Aggregate Intrinsic Value, Ending Balance Outstanding | $
Aggregate Intrinsic Value, Exercisable | $

Commitment and Contingencies (D

Commitment and Contingencies (Details Narrative) - USD ($)	Sep. 24, 2020	Jul. 05, 2020	Jun. 05, 2020	Jun. 30, 2020	Dec. 31, 2019	Mar. 31, 2018	Sep. 30, 2020	Dec. 31, 2020
Lease description							The lease is for a period of 60 months commencing in February 2020 and expiring in February 2025.
Employee Incentive Stock Options [Member]
Number of stock option shares granted				1,800,000,000
Employment Agreement [Member] | Restricted Stock Units (RSUs) [Member]
Number of stock option shares granted
Busch Employment Agreement [Member] | Restricted Stock Units (RSUs) [Member]
Accrued director compensation							$ 70,000	$ 72,500
Lease Agreement [Member]
Lease description					The lease is for a period of 60 months, with options to continue leasing, commencing in February 2020 and expiring in February 2025.
Lease term					60 months
Lease expiration					Feb. 28, 2025
GMU License Agreement [Member]
License agreement, description							The Company entered into an exclusive license agreement ("License Agreement") with George Mason Intellectual Properties, a non-profit corporation formed for the benefit of George Mason University ("GMU") which: (1) grants an exclusive worldwide license, with the right to grant sublicenses, under the licensed inventions to make, have made, import, use, market, offer for sale and sell products designed, manufactured, used and/or marketed for all fields and for all uses, subject to the exclusions as defined in the License Agreement; (2) grants an exclusive option to license past, existing, or future inventions in the Company's field, from inventors that are obligated to assign to GMU and who have signed a memorandum of understanding acknowledging that developed intellectual property will be offered, subject to the exclusions as defined in the License Agreement; (3) the license and option granted specifically excludes biomarkers for lung, ovarian, and breast cancers in a diagnostic field of use and GMU inventions developed using materials obtained from third parties under agreements granting rights to inventions made using said materials and; (4) grants right to assign or otherwise transfer license so long as such assignment or transfer is accompanied by a change of control transaction and GMU is given 14 days prior notice. In addition, the Company is required to make an annual payment of $50,000 to GMU as well as pay GMU a quarterly royalty equal to the net revenue multiplied by one and one-half percent (1.5%), due on a quarterly basis or a quarterly sublicense royalty equal to the net revenue multiplied by fifteen percent (15%). Further, the Company has the right of first refusal for all technology associated with RPPA technology from GMU.
Accrued royalty fees							$ 832
Accrued license fees							2,083
NIH License Agreement [Member]
License agreement, description						The Company entered into a license agreement ("License Agreement") with the National Institutes of Health ('NIH") which grants the Company an exclusive United States license for certain patents. Pursuant to the License Agreement, the Company is required to make an annual payment of $6,000 to the NIH as well as pay the NIH a royalty equal to the net sales multiplied by three percent (3.0%) every June 30th and December 31st of the year. In addition, a sublicense royalty equal to the net revenue multiplied by ten percent (10%) will be payable upon sublicensing.
Accrued royalty fees							19,834
Annual royalty						$ 5,000
Other Contingencies [Member]
Contingent liability							64,040
Notes payable, outstanding principal							40,000
Accrued interest payable							$ 24,040
Dr. Michael Ruxin [Member] | Employment Agreement [Member]
Salaries			$ 300,000
Annual discretionary bonus percentage			150.00%
Dr. Michael Ruxin [Member] | Employment Agreement [Member] | Restricted Stock Units (RSUs) [Member] | 2020 Equity Incentive Plan [Member]
Number of stock option shares granted			49,047,059
Dr. Michael Ruxin [Member] | Employment Agreement [Member] | Stock Option [Member] | 2020 Equity Incentive Plan [Member]
Number of stock option shares granted			420,691,653
Jeffrey Busch [Member] | Busch Employment Agreement [Member]
Salaries			$ 60,000
Jeffrey Busch [Member] | Busch Employment Agreement [Member] | Restricted Stock Units (RSUs) [Member] | 2020 Equity Incentive Plan [Member]
Number of stock option shares granted			49,047,059
Jeffrey Busch [Member] | Busch Employment Agreement [Member] | Stock Option [Member] | 2020 Equity Incentive Plan [Member]
Number of stock option shares granted			420,691,653
Thomas E. Chilcott, III [Member] | Offer Letter [Member]
Salaries	$ 225,000
Number of stock option shares granted	94,545,096
Employee bonus, description	He will be eligible to receive the following bonuses: $5,000 if the Company's next Annual Report on Form 10-K is filed on or prior to December 12, 2020; $5,000 if the Company files a registration statement on Form S-1 on or prior to January 15, 2021; $5,000 if the Company completes a capital raise of at least $3,000,000 on or prior to Apri1 15, 2021; $20,000 if the Company completes a capital raise of at least $10,000,000 on or prior to September 30, 2021; and $15,000 if the Company successfully lists on a Nasdaq stock market on or before December 31, 2021.
Accrued bonuses
Consultant [Member] | Scientific Advisory Board Service Agreement [Member]
Monthly compensation		$ 2,000
Other payments		$ 1,500
Consultant [Member] | Scientific Advisory Board Service Agreement [Member] | 2020 Equity Incentive Plan [Member]
Number of stock option shares granted		88,786,943					88,786,943
Consultant [Member] | Pathology Advisory Board Service Agreement [Member]
Monthly compensation		$ 272
Other payments		$ 1,500
Consultant [Member] | Pathology Advisory Board Service Agreement [Member] | 2020 Equity Incentive Plan [Member]
Number of stock option shares granted		77,972,192					77,972,192

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	12 Months Ended
	Sep. 30, 2020USD ($)
Operating loss carryforward	$ 38,198,187
Increase in valuation allowance	865,783
Net operating loss carryforward	9,790,195
Tax benefit carry forward	$ 8,050,201
Loss carryforward expiration year	expire in 2037
Act's Effective Date [Member]
Operating loss carryforward	$ 1,739,994

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Taxes and Reconciliation (Details) - USD ($)	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income tax deduction (benefit) at U.S. statutory rate of 21%	$ (665,756)	$ (335,595)
Income tax deduction (benefit) - state	(146,783)	(73,980)
Non-deductible (income) expenses	(53,244)	10,483
Change in valuation allowance	865,783	399,402
Total provision for income tax

Income Taxes - Schedule of Ef_2

Income Taxes - Schedule of Effective Income Taxes and Reconciliation (Details) (Parenthetical)	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Percentage of statutory rate	21.00%	21.00%

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($)	Sep. 30, 2020	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Net operating loss carryforward	$ 9,790,195	$ 8,924,412
Total deferred tax asset	9,790,195	8,924,412
Less: Valuation allowance	(9,790,195)	(8,924,412)
Net deferred tax asset

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)

Jul. 26, 2021shares

Jul. 02, 2021USD ($)

Jun. 10, 2021ft²

May 12, 2021USD ($)$ / sharesshares

Apr. 26, 2021USD ($)

Jul. 31, 2021USD ($)$ / sharesshares

Jun. 30, 2021USD ($)$ / sharesshares

May 31, 2021USD ($)

Apr. 14, 2021USD ($)$ / sharesshares

Sep. 30, 2020USD ($)$ / sharesshares

Sep. 30, 2019USD ($)$ / sharesshares

Sep. 22, 2020$ / shares

Jun. 05, 2020$ / shares

Subsequent Event [Line Items]

Common stock, par value | $ / shares

$ 0.0001

$ 0.0001

Proceeds from related party debt

$ 115,050

Preferred stock, par value | $ / shares

$ 0.0001

$ 0.0001

Preferred stock, shares authorized | shares

26,667

26,667

Maximum [Member]

Subsequent Event [Line Items]

Common stock, par value | $ / shares

$ 0.0001

Common Stock [Member]

Subsequent Event [Line Items]

Number of stock | shares

5,081,550,620

Common Stock [Member] | Maximum [Member]

Subsequent Event [Line Items]

Common stock, par value | $ / shares

$ 0.0001

Stock Warrants [Member]

Subsequent Event [Line Items]

Warrants outstanding | shares

856,674,588

Warrant exercise price | $ / shares

$ 0.0025

Subsequent Event [Member]

Subsequent Event [Line Items]

Plaintiffs amount

$ 1,000,000

Shares transferred | shares

10,000

Subsequent Event [Member] | Series F Preferred Stock [Member]

Subsequent Event [Line Items]

Preferred stock, par value | $ / shares

$ 0.0001

Preferred stock, shares authorized | shares

1,000

Stated value of preferred stock | $ / shares

$ 2,000

Dividend rate

8.00%

Dividend description

Dividends shall be paid within 15 days after the end of each month ("Dividend Payment Date"), at the option of the Holder in cash or through the issuance of shares of Common Stock.

Conversion of preferred stock

Each share of Series F Preferred Stock is convertible into shares of common stock any time after the initial issuance date at the Conversion Price which is the lesser of: (i) $0.00313 or (ii) 75% of the average closing price of the common stock during the prior five trading days on the principal market, subject to adjustment as provided in the Series F Certificate of Designation. Provided, however, the Conversion Price shall never be less than $0.0016. The number of shares of common stock issuable upon conversion shall be determined by multiplying the number of outstanding shares by the stated value per share of $2,000 plus additional amount by the Conversion Price.

Subsequent Event [Member] | Subscription Agreement [Member] | Fourteen Accredited Investors [Member] | Common Stock [Member]

Subsequent Event [Line Items]

Sale of stock issued | shares

431,309,904

Common stock, par value | $ / shares

$ 0.0001

Sale of stock price per share | $ / shares

$ 0.00313

Aggregate purchase price

$ 1,350,000

Subsequent Event [Member] | Promissory Note Agreement [Member] | Jeffrey Busch [Member]

Subsequent Event [Line Items]

Debt instrument, face amount

$ 100,000

Proceeds from related party debt

$ 100,000

Debt instrument, interest rate

1.00%

Debt instrument, maturity date

Apr. 1, 2022

Prepaymet percentage of outstanding principal and accrued interest

1.00%

Subsequent Event [Member] | Securities Purchase Agreement [Member] | Stock Warrants [Member]

Subsequent Event [Line Items]

Warrant exercise price | $ / shares

$ 0.00313

Subsequent Event [Member] | Securities Purchase Agreement [Member] | Stock Warrants [Member] | Maximum [Member]

Subsequent Event [Line Items]

Warrants outstanding | shares

63,897,764

Subsequent Event [Member] | Securities Purchase Agreement [Member] | Investors [Member] | Series F Preferred Stock [Member]

Subsequent Event [Line Items]

Sale of stock issued | shares

500

Aggregate investment amount

$ 1,000,000

Stated value of preferred stock | $ / shares

$ 2,000

Dividend rate

8.00%

Conversion of preferred stock

The number of shares of common stock issuable upon conversion of the Series F Preferred is determined by dividing the stated value of the number of shares being converted, plus any accrued and unpaid dividends, by the lesser of: (i) $0.00313 and (ii) 75% of the average closing price of the Company's common stock during the prior five trading days; provided, however, the conversion price shall never be less than $0.0016. In addition, the investor was issued a Warrant to purchase an amount of common stock equal to 20% of the shares of common stock issuable upon conversion of the Series F Preferred at an exercise price of $0.00313 per share (subject to adjustment as provided therein) until July 30, 2026.

Subsequent Event [Member] | Securities Purchase Agreement [Member] | Investors [Member] | Convertible Note [Member]

Subsequent Event [Line Items]

Debt instrument, face amount

$ 1,000,000

Original issuance discount

$ 15,800

Debt instrument, interest rate

8.00%

Debt instrument, maturity date

May 12, 2026

Prepaymet percentage of outstanding principal and accrued interest

110.00%

Default interest rate

10.00%

Debt instrument, convertible conversion price | $ / shares

$ 0.00313

Subsequent Event [Member] | Securities Purchase Agreement [Member] | Investors [Member] | Convertible Note [Member] | First Tranche [Member]

Subsequent Event [Line Items]

Proceeds from related party debt

$ 333,334

Subsequent Event [Member] | Securities Purchase Agreement [Member] | Investors [Member] | Convertible Note [Member] | Second Tranche [Member]

Subsequent Event [Line Items]

Proceeds from related party debt

$ 333,333

Subsequent Event [Member] | Securities Purchase Agreement [Member] | Investors [Member] | Convertible Note [Member] | Third Tranche [Member]

Subsequent Event [Line Items]

Proceeds from related party debt

$ 333,333

Subsequent Event [Member] | Securities Purchase Agreement [Member] | Investors [Member] | Stock Warrants [Member]

Subsequent Event [Line Items]

Aggregate investment amount

$ 1,000,000

Fair value of warrants

$ 984,200

Number of stock | shares

63,897,764

Subsequent Event [Member] | Lease Amendment [Member]

Subsequent Event [Line Items]

Area of land | ft²

4,734

Monthly rent, description

The Company must pay a monthly base rent of; (i) $5,660 for the year from 3/1/25 to 2/28/26 and (ii) $5,829 for each year thereafter. In addition, the Company must pay a monthly base rent for the Expanded Premises of; (i) $4,537 in the first year; (ii) $4,673 in the second year; (iii) $4,813 in the third year; (iv) $4,957 in the fourth year and; (v) $5,106 in the fifth year.